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A B S T R A C T
Background
Persistent cough is a common clinical problem. Despite thorough investigation and empirical management, a considerable proportion
of those people with subacute and chronic cough have unexplained cough, for which treatment options are limited. While current
guidelines recommend inhaled corticosteroids (ICS), the research evidence for this intervention is conflicting.
Objectives
To assess the effects of ICS for subacute and chronic cough in adults.
Search methods
We searched the Cochrane Airways Group Register of Trials, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE
and ClinicalTrials.gov in December 2012 and conducted handsearches.
Selection criteria
Two authors independently assessed all potentially relevant trials. All published and unpublished randomised comparisons of ICS versus
placebo in adults with subacute or chronic cough were included. Participants with known chronic respiratory disease and asthma were
excluded. Studies of cough-variant asthma and eosinophilic bronchitis were eligible.
Data collection and analysis
Two authors independently extracted data pertaining to pre-defined outcomes. The primary outcome was the proportion of participants
with clinical cure or significant improvement (over 70% reduction in cough severity measure) at follow up (clinical success). The
secondary outcomes included proportion of participants with clinical cure or over 50% reduction in cough severity measure at follow
up, mean change in cough severity measures, complications of cough, biomarkers of inflammation and adverse effects. We requested
additional data from study authors.
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Main results
Eight primary studies, including 570 participants, were included. The overall methodological quality of studies was good. Significant
clinical heterogeneity resulting from differences in participants and interventions, as well as variation in outcome measures, limited
the validity of comparisons between studies for most outcomes. Data for the primary outcome of clinical cure or significant (> 70%)
improvementwere available for only three studies, whichwere too heterogeneous to pool. Similarly, heterogeneity in study characteristics
limited the validity of meta-analysis for the secondary outcomes of proportion of participants with clinical cure or over 50% reduction in
cough severitymeasure and clinical cure. One parallel group trial of predominantly chronic cough with ’cough-variant asthma’ identified
a significant treatment effect and contributed to the majority of statistical heterogeneity for these outcomes. While ICS treatment
resulted in a mean decrease in cough score of 0.34 standard deviations (SMD -0.34; 95% CI -0.56 to -0.13; 346 participants), the
quality of evidence was low. Heterogeneity also prevented meta-analysis for the outcome of mean change in visual analogue scale score.
Meta-analysis was not possible for the outcomes of pulmonary function, complications of cough or biomarkers of inflammation due to
insufficient data. There was moderate quality evidence that treatment with ICS did not significantly increase the odds of experiencing
an adverse event (OR 1.67; 95% CI 0.92 to 3.04).
Authors’ conclusions
The studies were highly heterogeneous and results were inconsistent. Heterogeneity in study design needs to be addressed in future
research in order to test the efficacy of this intervention. International cough guidelines recommend that a trial of ICS should only
be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate
investigations.
P L A I N L A N G U A G E S U M M A R Y
Inhaled corticosteroids for adults with cough lasting over three weeks
Background
There is often no obvious cause for coughs that last more than three weeks. Lack of a clear cause makes the cough difficult to treat.
Current guidelines recommend that in many cases people with cough lasting longer than three weeks be given inhaled corticosteroids
(ICS), which are commonly used to treat asthma and other diseases involving airway inflammation.
Review question
We wanted to find out if taking inhaled steroids in adults with cough lasting three weeks or longer were beneficial.
We looked at evidence from clinical trials. We analysed the effects of ICS compared with placebo on cough severity, lung function,
complications of cough and airway inflammation, as well as the safety of this treatment.
Study characteristics
We found eight studies on 570 people with cough lasting over three weeks. Studies included different types of participants in terms of
age, duration of coughing and risk factors for cough. Studies also varied in types of ICS, doses, treatment lengths and types of inhaler
used. Cough severity was measured using different scales.
Key results
We looked at the proportion of people who were clinically cured or showed a significant improvement in cough severity as our primary
outcome, but the data were too mixed to be able draw any conclusions. These differences between studies also prevented meaningful
pooling of study results for proportion of people showing improvement in cough and average improvement in one specific type of cough
scale. There was low quality evidence that ICS reduced cough severity score. There was not enough data about changes in pulmonary
function, complications of cough and markers of inflammation to allow pooling of results.There was evidence of moderate quality that
ICS treatment did not increase the risk of adverse events.
Conclusion and future work
This review has shown that the effects of ICS for subacute and chronic cough are inconsistent. Further studies with more consistent
patient populations, interventions, outcome measures and reporting are needed to determine whether ICS help subacute and chronic
cough in adults.
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B A C K G R O U N D
Cough, defined as “a forced expulsive manoeuvre, usually against
a closed glottis and . . . associated with a characteristic sound”
(Morice 2006), constitutes both a vital protective reflex and a com-
mon symptom of many pulmonary and several extra-pulmonary
conditions.
In adults, subacute cough is defined as a cough of three to eight
weeks duration, with a large proportion of cases due to postinfec-
tious cough (Irwin 2006a; Kwon 2006). Chronic cough persists
for more than eight weeks (Gibson 2010; Irwin 2006a; Morice
2004; Morice 2006), and, in most cases, is attributed to asthma,
rhinitis or gastro-oesophageal reflux disease (GORD) (Irwin 1998;
Gibson 2010), as well as other pulmonary conditions. While the
prevalence of subacute cough is less clear, up to 40% of the pop-
ulation report having chronic cough (Morice 2004).
Description of the condition
Cough of intrapulmonary aetiology (lung-based cause) occurs
when mechanical or chemical irritants activate vagal sensory nerve
fibres in the airways and lungs, triggering a reflex arc that results
in a co-ordinated motor output (Canning 2007). While failure
of this defence mechanism can be life-threatening, increased sen-
sitivity to the cough reflex is associated with excessive, persistent
cough (Howden 2010).
Chronic cough is associated with a substantial deterioration in
quality of life, comparable to severe chronic obstructive pulmonary
disease (COPD; French 1998), with diverse effects on all aspects of
health, for example, causing musculoskeletal chest pain, sleep dis-
turbance, anxiety and impaired social functioning (Birring 2003;
French 2002; French 2004; McGarvey 2006). Given this associ-
ated morbidity, it is not surprising that cough is themost common
symptom prompting presentation to general practice in Australia
(Britt 2011). Cough is also associated with high rates of secondary
care consultations, with chronic cough accounting for up to 38%
of all referrals to respiratory physicians (Irwin 1990; McGarvey
1998a). In addition to these significant time costs, annual expen-
diture on over-the-counter and prescription treatments is proba-
bly in the order of billions of US dollars (Irwin 1998).
While clinical guidelines recommend treatment of the underlying
condition (Gibson 2010; Irwin 2006a; Morice 2007), a specific
cause is not established in up to 46% of people who are described
as having idiopathic or unexplained cough (Haque 2005; Irwin
2006b; Levine 2008; McGarvey 1998b; O’Connell 1994; Poe
1989).
Description of the intervention
Inhaled corticosteroids (ICS) may be administered via a me-
tered dose inhaler (MDI), dry powder inhaler (DPI) or nebuliser
(Bateman 2009). Through altering transcription of inflammatory
mediators and direct actions on inflammatory cells, ICS suppress
airway inflammation (Barnes 2006). Inhaled steroids are first-line
therapy for many inflammatory airway diseases, including asthma
(Bateman 2009), and are indicated for people with severe COPD
and frequent exacerbations (Yang 2012).
ICS may cause local side effects including oropharyngeal candidi-
asis (thrush in mouth/throat), dysphonia (hoarseness) and cough
(Roland 2004). While direct delivery into the airways by inhala-
tion significantly reduces the risk of systemic (whole body) side
effects, absorption from the lungs can lead to complications in-
cluding easy bruising, reduced bone mineral density and adrenal
suppression (Bateman 2009; Lipworth 1999).
How the intervention might work
Persistent cough as an isolated symptom (Jatakanon 1999; Lee
2001; McGarvey 1999), and also in the context of known respi-
ratory disease (Brightling 2000; Niimi 1998), is often associated
with airway inflammation, which contributes to cough reflex hy-
persensitivity (Birring 2011; Morice 2010; Nair 2010). Through
reducing this airway inflammation, ICS may be useful in treating
subacute and chronic cough.
Why it is important to do this review
Clinical guidelines recommend empirical ICS treatment for non-
specific and refractory cough (Gibson 2010), suspected cough-
variant asthma (CVA) (Irwin 2006a; Morice 2004; Morice 2006),
non-asthmatic eosinophilic bronchitis (Irwin 2006a; Morice
2004; Morice 2006), and atopic cough (Morice 2006). The ef-
ficacy of this intervention, however, remains contentious, with
randomised controlled trials yielding conflicting results. A recent
Cochrane systematic review has questioned the efficacy of ICS for
non-specific cough in children (Tomerak 2009), and a Cochrane
systematic review of ICS for subacute cough in children has re-
cently been published (Anderson-James 2013). By providing sys-
tematic evidence relating to this intervention, this review aims to
clarify uncertainty in current clinical practice and to elucidate the
potential benefits of ICS in reducing the significant burden asso-
ciated with subacute and chronic cough in adults. Through eval-
uating the strengths and limitations of current research evidence,
this review also aims to inform future research directions.
O B J E C T I V E S
To assess the effects of ICS for subacute and chronic cough in
adults.
6Inhaled corticosteroids for subacute and chronic cough in adults (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
M E T H O D S
Criteria for considering studies for this review
Types of studies
As defined a priori in a published protocol (Johnstone 2011), we
reviewed all published and unpublished randomised controlled
trials (RCTs) comparing ICS with placebo for treatment of suba-
cute and chronic cough in adults.
Types of participants
We considered all studies that included adults (over 18 years)
with subacute or chronic cough, defined respectively as three to
eight weeks, or more than eight weeks duration, respectively. We
excluded participants with other known chronic respiratory dis-
eases including asthma, chronic obstructive pulmonary disease and
bronchiectasis, however, we included people with CVA (without
demonstrated bronchodilator reversibility) and eosinophilic bron-
chitis (eosinophilic airway inflammationwith sputumeosinophilia
of greater than 2.5%; Gibson 2002).
Types of interventions
We included all randomised controlled comparisons of ICS versus
placebo. ICS could be administered by MDI, DPI or nebuliser.
Where trials included the use of other medications, all participants
had to have equal access to such medications. We excluded trials
without a placebo comparison group.
Types of outcome measures
Primary outcomes
1. Proportion of participants with clinical cure or significant
improvement (over 70% reduction in cough severity measure) at
follow up (clinical success).
Secondary outcomes
1. Proportion of participants with clinical cure or over 50%
reduction in cough severity measure at follow up.
2. Proportion of participants with clinical cure at follow up.
3. Mean change in objective and subjective cough severity
measures - cough frequency, cough receptor sensitivity, quality of
life, Likert scale, visual analogue scale (VAS), level of interference
of cough, cough diary.
4. Mean change in pulmonary function measures - bronchial
hyper-responsiveness (BHR), spirometry, peak expiratory flow
(PEF).
5. Complications of cough - requirement for medication
change, time off work.
6. Biomarkers of inflammation - sputum biomarkers (total and
differential cell counts, inflammatory mediators), exhaled gases.
7. Adverse effects of intervention - local side effects
(oropharyngeal candidiasis, dysphonia, cough) and systemic side
effects (easy bruising, reduced bone mineral density, adrenal
suppression).
Where a study reported two or more cough severity measures,
we used the first from the following hierarchy of cough severity
measures:
1. Objective cough indices - cough frequency, cough receptor
sensitivity.
2. Symptomatic measures as assessed by the participant -
quality of life, Likert scale, VAS, level of interference of cough,
cough diary.
3. Symptomatic measures as assessed by clinicians - Likert
scale, VAS, level of interference of cough.
Where a study reported two or more cough severity measures of
equal ranking on the hierarchy, we used the measure most com-
parable to those reported by other studies in the meta-analysis.
Search methods for identification of studies
Electronic searches
Trials were identified by searches of the following databases:
• The Cochrane Airways Group Trials Register (CAGR)
(December 2012);
• Cochrane Central Register of Controlled Trials
(CENTRAL), (The Cochrane Library 2012, Issue 12);
• MEDLINE (Ovid): (1948 to November week 3, 2012);
• EMBASE (Ovid): (1980 to week 49, 2012);
• ClinicalTrials.gov (December 2012).
The searches were conducted in December 2012, with no restric-
tion on language of publication. Search strategies are listed in
Appendix 1, Appendix 2, Appendix 3, Appendix 4 and Appendix
5.
Searching other resources
We reviewed the reference lists of all primary studies and review
articles for additional references. We asked contact authors of in-
cluded trials to identify other published and unpublished studies.
We also searched manufacturers’ clinical trial registries.
Data collection and analysis
Selection of studies
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Two reviewers (KJ, IY) independently assessed all potentially rel-
evant studies identified through the search strategy for inclusion
in the review. We resolved any disagreements through discussion.
Data extraction and management
For each trial that satisfied the inclusion criteria, we recorded the
following information using a data collection form:
• Design and methodology: year of study, source of funding,
design, randomisation, blinding (including allocation
concealment and blinding of participants, care providers and
outcome assessors) and statement of withdrawals.
• Participants: study setting, inclusion and exclusion criteria,
participant recruitment details including number eligible,
number enrolled, characteristics of study population (including
age range, sex, ethnicity, diagnosis, other symptoms), number in
treatment and control groups, baseline characteristics of
treatment and control groups, number completing trial and
number of withdrawals including reasons for withdrawal (e.g.
clinical, side-effects, refusal) and whether intention-to-treat
analysis is possible.
• Interventions: drug, dose, type of administration (i.e. MDI,
DPI, nebulised), duration of intervention and co-interventions.
• Outcomes: primary and secondary outcomes as described
above.
Two reviewers (KJ, IY) independently extracted data from in-
cluded studies. Where required, we requested missing informa-
tion from the study authors.
We calculated budesonide equivalent doses from the ranges out-
lined in the Global strategy for asthma management and prevention
guidelines (Bateman 2009).
Assessment of risk of bias in included studies
Two reviewers (KJ, IY) independently assessed risk of bias for each
study using the criteria outlined in The Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We resolved
any disagreement by consensus.
We assessed the risk of bias according to the following domains:
1. Random sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Blinding of participants and personnel (performance bias).
4. Blinding of outcome assessment (detection bias).
5. Incomplete outcome data (attrition bias).
6. Selective reporting (reporting bias).
7. Other bias.
We graded each potential source of bias as being high, low or at
unclear risk of bias.
Measures of treatment effect
For all dichotomous outcomes, we calculated the odds ratio (OR)
and 95% confidence interval (CI). We calculated the mean dif-
ference (MD) and 95% CI for all continuous outcomes. Where
studies used different measurement scales, we calculated the stan-
dardised mean difference (SMD). In the case of missing data due
to drop-outs, we performed amodified intention-to-treat analysis.
We compared the characteristics of each included study to deter-
mine whether meta-analysis of results was possible. We included
all studies that satisfied the inclusion criteria and reported one or
more outcomes of interest in the meta-analysis. We determined
numbers needed to treat to benefit (NNTB) using an online cal-
culator (Cates 2008).
We performed all statistical analysis using Review Manager 5
(RevMan) software.
Unit of analysis issues
Wedescribed all cross-over trials, and included them inmeta-anal-
ysis where first period data was available.Where this was not avail-
able, we analysed data using the generic inverse variance method.
Handling of cross-over trials in these ways differed from our pro-
tocol (see Differences between protocol and review).
Dealing with missing data
We contacted investigators or study sponsors in order to verify key
study characteristics and obtain missing numerical outcome data,
where possible.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis. We assessed the importance of the level of hetero-
geneity identified as described in The Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). Where possible,
we explored substantial heterogeneity by pre-specified subgroup
analysis.
Assessment of reporting biases
We assessed selective reporting within each trial by comparing
the protocol and final published study, or otherwise the methods
and results sections. Where we suspected reporting bias, we at-
tempted to contact study authors asking them to provide missing
outcome data. Where this was not possible, and the missing data
were thought to introduce serious bias, we explored the impact
of including such studies in the overall assessment of results by
means of a sensitivity analysis. We explored publication bias us-
ing a funnel plot where meta-analysis with at least ten studies was
possible.
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Data synthesis
We used a fixed-effect model to calculate the summary ORs, MDs
and their 95% CIs. Where there were concerns about statisti-
cal heterogeneity, we used a random-effects model. Where meta-
analysis was not possible, or appropriate, we undertook a narra-
tive review of the findings. We determined the quality of evidence
for each pooled outcome based on the Grading of Recommen-
dations Assessment, Development and Evaluation (GRADE) ap-
proach using GRADEprofiler 3.2.
Subgroup analysis and investigation of heterogeneity
Where possible, we carried out the following subgroup analyses
for the primary outcome:
1. Dose of ICS (low to medium defined as < (less than) 800
µg/day budesonide equivalent and high defined as > (more than
or equal to) 800 µg/day budesonide equivalent).
2. Final diagnosis such as eosinophilic bronchitis, CVA,
unexplained cough.
3. Duration of treatment (up to 4 weeks and > (more than) 4
weeks).
4. Duration of cough (3 to 8 weeks and > 8 weeks).
Sensitivity analysis
Where possible, we used sensitivity analysis to assess the robustness
of the overall outcomes to the following factors:
1. Variation in inclusion criteria.
2. Risk of bias.
3. Study size.
4. Analysis using random-effects model.
5. Analysis by treatment received versus intention-to-treat.
6. Method of inhalation (e.g. MDI, DPI, nebuliser).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
Results of the search
A total of 1051 records were retrieved from electronic and hand-
searches. Of these, eight studies reported in 16 references met the
inclusion criteria. For full details of the study selection process,
please see Figure 1.We excluded 12 studies; reasons for their exclu-
sion are provided in the Characteristics of excluded studies table.
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Figure 1. Study flow diagram showing study selection process.
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Included studies
Key study characteristics and outcomes of the included studies are
summarised in Characteristics of included studies and Figure 2.
Figure 2. Summary of included studies.AbbreviationsBHR = bronchial hyper-responsivenesscells = sputum
total and/or differential cell countsdose = budesonide equivalent daily doseDPI = dry powder inhalerECP =
eosinophilic cationic proteinFEF25−75% = forced expiratory flow 25%-75%FEV1 = forced expiratory volume in 1
secondFVC = forced vital capacitygases = exhaled gases (CO, NO)meds = additional medication useMDI =
metered dose inhalernight = nocturnal awakeningsother = other sputum biomarkers (MPO, PGE2, LTB4, Cys-
LT, IL-8, TNF-alpha, fibrinogen, albumin, substance P)PEF = peak expiratory flowURTI = upper respiratory
tract infection
11Inhaled corticosteroids for subacute and chronic cough in adults (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Study design
Of the eight randomised controlled trials identified, five were par-
allel group trials (Pizzichini 1999; Ponsioen 2005; Pornsuriyasak
2005; Ribeiro 2007; Rytilä 2008), two were cross-over trials that
described first period results and were, therefore, able to be treated
as parallel group trials (Boulet 1994; Evald 1989), and one was
a cross-over trial with a two-week washout period between treat-
ments (Chaudhuri 2004).
Sample sizes
The number of participants enrolled in each study ranged from
14 to 144 (Boulet 1994; Rytilä 2008).
Setting
Study locations included Brazil (Ribeiro 2007), Canada (Boulet
1994; Pizzichini 1999; Rytilä 2008), Denmark (Evald 1989), Fin-
land, Greece, Hungary, Norway, Sweden (Rytilä 2008), Thailand
(Pornsuriyasak 2005), the Netherlands (Ponsioen 2005), and the
United Kingdom (Chaudhuri 2004; Rytilä 2008). Participants
were recruited from hospital or specialist clinics (Boulet 1994;
Evald 1989; Pornsuriyasak 2005; Rytilä 2008), primary care prac-
tices (Ponsioen 2005), or a combination of community and hos-
pital settings (Chaudhuri 2004; Pizzichini 1999; Ribeiro 2007).
Participants
A total of 570 participants with cough were randomly allocated
to receive ICS or placebo. All studies included adults only, with
the exception of one smaller study that included participants aged
15 to 65 years (Evald 1989). While children aged over 15 years
were also eligible for inclusion in Pornsuriyasak 2005, the mean ±
SD age of participants (40.6 years ± 11.8 years for ICS, 38.8 years
± 13.0 years for placebo) suggests that this is less likely to have
influenced the results of this study. Inclusion criteria for duration
of cough ranged from at least two weeks (Ponsioen 2005) through
to more than one year (Chaudhuri 2004; Pizzichini 1999). Un-
published data including only those participants with cough for
at least three weeks was obtained for the study that included peo-
ple with acute cough of two weeks (Ponsioen 2005). Four studies
included people with both subacute and chronic cough. Partici-
pants with subacute cough predominated in two studies (Ponsioen
2005; Pornsuriyasak 2005), and participants with chronic cough
predominated in two (Boulet 1994; Evald 1989). Four studies ex-
amined participants with chronic cough only (Chaudhuri 2004;
Pizzichini 1999; Ribeiro 2007; Rytilä 2008). Most participants
had nonspecific cough, except for those in a study specifically
examining post-upper respiratory tract infection (URTI) cough
(Pornsuriyasak 2005).
All studies excluded people with asthma, on the basis of history or
spirometry, and those with known respiratory disease through his-
tory, examination, spirometry or chest X-ray. There was significant
heterogeneity in terms of other eligibility criteria. Five studies ex-
cluded smokers (Boulet 1994; Chaudhuri 2004; Pizzichini 1999;
Pornsuriyasak 2005;Rytilä 2008). Peoplewith demonstratedBHR
were excluded from two studies (Boulet 1994; Pizzichini 1999),
and only three people with amildly positive bronchial provocation
test were included in one study of 30 participants (Pornsuriyasak
2005). Four studies excluded people taking medications that po-
tentially contribute to cough (Boulet 1994; Chaudhuri 2004;
Pizzichini 1999; Pornsuriyasak 2005). Five studies excluded peo-
plewith recent inhaled or oral steroid use (Boulet1994;Chaudhuri
2004; Evald 1989; Pizzichini 1999; Ribeiro 2007). Six studies
excluded people with recent respiratory infection (Boulet 1994;
Chaudhuri 2004; Evald 1989; Pizzichini 1999; Ribeiro 2007;
Rytilä 2008). It was unclear whether medications causing cough,
recent steroid use or recent respiratory infection were among the
exclusion criteria for Ponsioen 2005. People with GORD were
excluded from three studies (Pornsuriyasak 2005; Ribeiro 2007;
Rytilä 2008), and were specifically permitted in one study where
this condition was treated (Pizzichini 1999). People with postnasal
drip (PND), sinusitis or both were excluded from three studies
(Ponsioen 2005; Ribeiro 2007; Rytilä 2008), and permitted in two
studies where treated (Pizzichini 1999; Rytilä 2008).
Interventions
All trials compared ICS with placebo. The ICS used were be-
clomethasone, budesonide, fluticasone and mometasone. Daily
budesonide equivalent doses of ICS ranged from 320 µg/day
(Evald 1989), to 1600 µg/day (Boulet 1994; Chaudhuri 2004;
Ponsioen 2005), with two trials investigating low to medium dose
ICS and six trials investigating high dose ICS. Dose frequency
ranged from one puff per day (Rytilä 2008) to two puffs four
times daily (Boulet 1994). Treatment duration was two weeks
in five studies (Chaudhuri 2004; Evald 1989; Pizzichini 1999;
Ponsioen 2005; Ribeiro 2007), four weeks in two studies (Boulet
1994; Pornsuriyasak 2005) and eight weeks in the remaining study
(Rytilä 2008). ICS was administered by DPI or MDI in four stud-
ies each. Two studies of MDI reported use of a spacer (Boulet
1994; Ponsioen 2005).
Outcomes
Cough severity
All studies reported some form of symptomatic measure assessed
by the participant. This included cough symptom scores, VAS
and cough diaries. Statistical reporting varied between studies.
Changes in cough severity were reported as mean change from
baseline, pre- and post-intervention means and differences of dif-
ferences. Primary outcome data were available for only three stud-
ies (Boulet 1994; Ponsioen 2005; Ribeiro 2007).None of the stud-
ies used cough meters to quantify cough objectively.
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Pulmonary function
Four studies assessed BHR (Boulet 1994; Ponsioen 2005;
Pornsuriyasak 2005; Rytilä 2008), and three studies reported this
outcome (Boulet 1994; Ponsioen 2005; Pornsuriyasak 2005). Four
studies stated that they investigated forced expiratory volume
in one second (FEV1) (Evald 1989; Pizzichini 1999; Ponsioen
2005; Pornsuriyasak 2005), though this outcome was only re-
ported in two (Ponsioen 2005; Pornsuriyasak 2005). Three inves-
tigated forced vital capacity (FVC) (Evald 1989; Pizzichini 1999;
Pornsuriyasak 2005), although data was reported in only one of
these trials (Pornsuriyasak 2005). One study measured change in
forced expiratory flow 25% to 75% (FEF25−75%) (Pornsuriyasak
2005). Two studies examined changes in peak expiratory flow
(Evald 1989; Rytilä 2008).
Complications of cough
Studies investigated complications of cough including: the need
for additional medication (Ponsioen 2005, Pornsuriyasak 2005,
Rytilä 2008), nocturnal awakenings (Evald 1989, Ponsioen 2005,
Ribeiro 2007), and days off work (Ponsioen 2005).
Sputum biomarkers of inflammation
Several studies measured changes in sputum biomarkers of inflam-
mation, including total and differential cell counts (Chaudhuri
2004; Pizzichini 1999), eosinophils (Chaudhuri 2004; Pizzichini
1999; Rytilä 2008), and eosinophilic cationic protein (ECP)
(Chaudhuri 2004; Pizzichini 1999; Rytilä 2008). Two studies also
investigated a range of other inflammatory mediators (Chaudhuri
2004; Pizzichini 1999). Chaudhuri 2004 also assessed the effect of
ICS on exhaled nitric oxide (eNO) and carbon monoxide (CO).
Adverse effects of intervention
Four studies investigated adverse effects, which were variably de-
fined in terms of local side effects (Pizzichini 1999), and adverse
effects that were considered to be related to treatment (Ponsioen
2005), or might be related to treatment (Rytilä 2008). In Ribeiro
2007, adverse effects was not defined as an outcome of interest,
but was reported in the results.
Excluded studies
Weexcluded12 studies; the reasons for their exclusions are detailed
in theCharacteristics of excluded studies table. Themost common
reason for exclusion was lack of a placebo comparison group.
Risk of bias in included studies
The overall quality of included studies was generally good, with
several studies having a low risk of bias in nearly all categories, as
shown in Figure 3. Unpublished data was sought for all studies.
For full details, please see Characteristics of included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
14Inhaled corticosteroids for subacute and chronic cough in adults (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Allocation
Reports of five studies described themethodof randomisationused
(Chaudhuri 2004; Pizzichini 1999; Ponsioen 2005; Ribeiro 2007;
Rytilä 2008). The risk of bias resulting from random sequence
generation was unclear in the remaining three studies.
The method of allocation concealment was adequately described
in five studies (Chaudhuri 2004; Pizzichini 1999; Ponsioen 2005;
Ribeiro 2007; Rytilä 2008), and was unclear in the remaining
three.
Blinding
All studies were described as double blind, resulting in a low risk
of performance bias and detection bias. Five studies described the
use of an identical or matching placebo inhaler (Chaudhuri 2004;
Pizzichini 1999; Ponsioen 2005; Ribeiro 2007; Rytilä 2008).
Incomplete outcome data
Two studies reported no drop-outs (Boulet 1994; Ribeiro 2007),
and, in the four studies that reported the groups fromwhich drop-
outs occurred, attrition rates were comparable for the treatment
and control groups, which resulted in an assessment of a low
risk of attrition bias for those trials (Pizzichini 1999; Ponsioen
2005; Pornsuriyasak 2005; Rytilä 2008). The remaining two stud-
ies did not state from which treatment group participants with-
drew, resulting in an assessment of an unclear risk of attrition bias
(Chaudhuri 2004; Evald 1989).
Selective reporting
Protocols were not available for any of the included studies, there-
fore, we compared the methods and results sections of all included
studies. Risk of reporting bias was unclear or high in the majority
of studies, with only two receiving a grading of low risk (Boulet
1994; Chaudhuri 2004). Reasons for a grading of unclear or high
risk of reporting bias included inadequate reporting of number
of people screened and eligible (Evald 1989; Pornsuriyasak 2005)
and outcomes in either themethods or results section (Evald 1989;
Pizzichini 1999; Ponsioen 2005; Ribeiro 2007; Rytilä 2008).
Other potential sources of bias
Chaudhuri 2004 noted no carry-over effect in the active treatment
group, resulting in a low risk of bias. The two cross-over trials
without a washout period described first period results, and thus
were able to be treated as parallel group trials, resulting in a low
risk of bias (Boulet 1994; Evald 1989).
The inclusion criterion of post-URTI cough was inadequately de-
fined in Pornsuriyasak 2005, which led to an unclear risk of bias
grading. Compliance was reasonably high in the two studies in
which it was monitored (Ponsioen 2005; Rytilä 2008).
Effects of interventions
See: Summary of findings for the main comparison Inhaled
corticosteroids (ICS) compared to placebo for adults with subacute
and chronic cough
Cough severity
Cross-over trials
Studies showing significant improvement
Chaudhuri 2004 investigated the efficacy of fluticasone 1000 µg/
day or placebo for two weeks among 93 non-smoking participants
who had had chronic cough for over a year, using a two-week
washout period between treatments. A significant reduction in
cough VAS score was noted after treatment with ICS compared
with placebo (mean ± standard error of the mean (SEM) 1.0 cm ±
0.3 cm). People taking medications causing cough as well as those
with recent steroid use and recent respiratory infection were not
eligible. Cough in these people was attributable to PND (34%),
GORD (20%), CVA (15%), bronchiectasis (10%), eosinophilic
bronchitis (6%), habitual cough (2%) and bronchitis (1%). Ten
people (11%) had idiopathic cough.
Parallel group trials
Studies showing no significant improvement
Two studies were designed as cross-over trials but reported first
period results (Boulet 1994; Evald 1989), which allowed them to
be treated as parallel group trials.
In a trial of 14 non-smokers with cough for more than four weeks,
Boulet 1994found no significant reduction in overall mean cough
scores after participants had received either beclomethasone 2000
µg/day or placebo for four weeks (MD -0.91 on a cough score
scale of 0 to 10; 95% CI -2.24 to 0.42). Participants had normal
airway responsiveness, were not taking medications causing cough
and had no history of recent oral, or inhaled, steroid use or recent
respiratory infection. Cough was attributable to GORD (36%),
PND (21%), both (31%) or no specific cause (21%).
The Evald 1989 trial of 40 non-smokers with daily dry cough for
at least one hour in more than half of the previous 30 days, found
no significant reduction in cough symptom scores for participants
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who received either beclomethasone 400 µg/day or placebo for
two weeks (data not reported). Smokers, people treated with anti-
asthmatic drugs, and those with recent respiratory infection were
excluded.
Four parallel group trials found that ICS did not signifi-
cantly reduce cough severity (Pizzichini 1999; Ponsioen 2005;
Pornsuriyasak 2005; Rytilä 2008).
In a study of 50non-smokerswhohad had chronic cough for over a
year, Pizzichini 1999 found no statistically significant reduction in
proportion with over 50% reduction in VAS score (OR 0.53; 95%
CI 0.06 to 4.91)following treatment with budesonide 800 µg/
day for two weeks versus placebo. People with BHR, medications
causing cough, recent steroid use, recent respiratory infection and
untreated GORD, PND and sinusitis were excluded.
A trial of inhaled fluticasone 1000 µg/day for two weeks versus
placebo in 135 participants with cough for at least two weeks
demonstrated a significant reduction in cough score among par-
ticipants (Ponsioen 2005). Smokers, people with BHR and those
with GORD were included. The eligibility of people taking med-
ications causing cough or those with recent steroid use or re-
cent respiratory infection was unclear. Unpublished data, how-
ever, that excluded the subgroup participants with acute cough
demonstrated that ICS treatment did not significantly increase the
odds of achieving clinical cure or more than 70% improvement in
cough severity measure. ICS treatment did not produce a signifi-
cant reduction in cough severity measure (MD -0.38 on a cough
score scale of 0 to 3; 95% CI -1.05 to 0.28).
Pornsuriyasak 2005 studied the effect of inhaled budesonide 800
µg/day versus placebo for four weeks among 30 participants with
persistent post-URTI cough for more than three weeks. Oral cor-
ticosteroids were terminated one week prior to entry into the
study. Exclusion criteria included smoking, BHR, use of medica-
tions causing cough, GORD and untreated sinusitis. Symptom
scores were not significantly different between the ICS and placebo
groups after two (MD -0.33; 95% CI -1.66 to 1.00) or four weeks
(MD -0.36; 95% CI -1.52 to 0.80) of treatment.
Rytilä 2008 investigated the efficacy of mometasone 400 µg/day
versus placebo for eight weeks in a trial with 144 participants who
had had cough for at least two months with at least one of the fol-
lowing additional symptoms: chest tightness, wheezing, shortness
of breath, or exercise-induced cough or wheezing. Smokers and
participants with recent respiratory infection, GORD, PND and
sinusitis were excluded. At follow up, there was no significant dif-
ference between the two groups in the proportion of participants
who were symptom free (29% ICS, 26% placebo, P value 0.7).
This study demonstrated no significant change in morning and
evening cough scores after four or eight weeks, despite a significant
improvement in total morning symptom score after eight weeks.
Studies showing significant improvement
One parallel group trial showed evidence of significant improve-
ment in cough severity with ICS treatment.
Ribeiro 2007 examined the effect of beclomethasone 1500 µg/
day versus placebo for two weeks among 64 participants who had
had chronic cough for at least eight weeks. Extrapulmonary causes
of cough, including GORD and PND, were excluded. Treatment
with ICS caused complete resolution in 82% of participants, com-
paredwith 15% in the placebo group (P value < 0.05), and resulted
in a significantly greatermean reduction in cough diary score (1.37
± 1.21 ICS, 0.54 ± 0.7 placebo) and VAS (79% ± 29.3% ICS,
15.1% ± 31.1% placebo).
Combined results
Proportion of participants with clinical cure or significant
improvement (over 70% reduction in cough severity
measure) at follow up (clinical success)
Only three studies contributed data for the primary outcomemea-
sure (Proportion of participants with clinical cure or significant
improvement (over 70% reduction in cough severity measure)
at follow up) in a form suitable for meta-analysis, although ulti-
mately we were unable to pool it due to heterogeneity. Each of
these studies examined high dose ICS via MDI for a maximum
of four weeks (Analysis 1.1). One of these studies found a sig-
nificant treatment effect (Ribeiro 2007). Participants had cough
for at least three weeks (Ponsioen 2005), more than four weeks
(Boulet 1994), or at least eight weeks (Ribeiro 2007). These stud-
ies differed in their eligibility criteria relating to exclusion of smok-
ers, BHR, medications causing cough (Boulet 1994), and those
with GORD or PND/sinusitis (Ribeiro 2007).While people with
recent steroid use and recent respiratory infection were excluded
from both Boulet 1994 and Ribeiro 2007, it was unclear whether
or not these people and those taking medications causing cough
were excluded from Ponsioen 2005. Substantial to considerable
clinical heterogeneity was reflected in statistical heterogeneity (I
2 = 85%). Therefore, pooling of results was deemed inappropri-
ate. The quality of evidence was low because of the unclear risk
of selection (Boulet 1994) and reporting bias in included studies
(Ponsioen 2005; Ribeiro 2007), and the small number of recorded
events.
Proportion of participants with clinical cure or over 50%
reduction in cough severity measure at follow up
Data pertaining to the proportion of participants who achieved
a more than 50% reduction in cough severity measure at fol-
low up were available from four studies, however heterogeneity in
study characteristics limited the validity of meta-analysis (Analysis
1.2). This did not include the cross-over study that found a sig-
nificant treatment effect (Chaudhuri 2004), or one of the larger
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higher quality studies which found no significant treatment ef-
fect (Rytilä 2008). Eligibility criteria for the studies were quite
heterogeneous. Cough duration ranged from at least three weeks
(Ponsioen 2005 subacute and chronic cough participants only), to
more thanone year (Pizzichini 1999), and studies varied in terms of
whether smoking, BHR, use ofmedications causing cough (Boulet
1994; Pizzichini 1999), recent steroid use (Boulet 1994; Pizzichini
1999; Ribeiro 2007), recent respiratory infection (Boulet 1994;
Pizzichini 1999; Ribeiro 2007), GORD (Pizzichini 1999 (un-
treated); Ribeiro 2007) and PND/sinusitis (Pizzichini 1999 (un-
treated); Ponsioen 2005; Ribeiro 2007) were among the exclusion
criteria. Each of these studies used high dose ICS for up to four
weeks duration via either DPI or MDI. Cough severity was mea-
sured in terms of cough symptom scores rated between 0 and 10
(Boulet 1994), or 0 and 3 (Ponsioen 2005), cough diary scores tak-
ing into account frequency, severity, duration and sleep interrup-
tion (Ribeiro 2007), and cough discomfort VAS scores (Pizzichini
1999; Ribeiro 2007). The quality of each of these studies was gen-
erally good. Among this diverse population using high dose ICS
for up to four weeks, the calculated I2 statistic was 81%, which
may represent substantial to considerable heterogeneity. The qual-
ity of evidence was low, with evidence downgraded due to the
unclear risk of selection bias in Boulet 1994 and small number of
events.
Proportion of participants with clinical cure at follow up
Data for the proportion of participants with clinical cure were
available from four studies (Analysis 1.3), one of which found a
significant difference in cure rates (Ribeiro 2007). Of these four
studies, one examined predominantly subacute cough (Ponsioen
2005), and three predominantly chronic cough (Boulet 1994;
Ribeiro 2007; Rytilä 2008). All studies had a low risk of bias in
nearly all categories. These studies were considered too heteroge-
neous in their participants, interventions and outcome measures
to pool. Studies varied as to whether smoking (Boulet 1994; Rytilä
2008), BHR (Boulet 1994), taking medications causing cough
(Boulet 1994), recent steroid use (Boulet 1994; Ribeiro 2007),
recent respiratory infection (Boulet 1994, Rytilä 2008), and ex-
trapulmonary causes were among the exclusion criteria (Ribeiro
2007; Rytilä 2008). Several of these eligibility criteria were un-
clear in Ponsioen 2005. Interventions included high dose ICS ad-
ministered via MDI for up to four weeks (Boulet 1994; Ponsioen
2005; Ribeiro 2007), and low dose ICS administered by DPI for
eight weeks (Rytilä 2008). Clinical cure was defined as a cough
symptom score of zero (Boulet 1994; Ponsioen 2005), resolution
of cough (Ribeiro 2007), or a total symptom score of 0 to 2 out of
36 (Rytilä 2008). For these reasons, pooling of these studies was
deemed inappropriate. Substantial to considerable heterogeneity
was reflected by the calculated I2 statistic of 82%. The overall
quality of this narrative evidence was low due to the unclear risk
of selection bias (Boulet 1994), and reporting bias in included
studies (Ponsioen 2005; Ribeiro 2007; Rytilä 2008), and the small
number of events.
Mean reduction in cough severity measure
Cough score
For mean change in cough symptom score, data were available
from five studies that included 364 participants; one of the studies
found ICS to be beneficial (Ribeiro 2007). Interventionswere high
dose ICS for two weeks (Ponsioen 2005; Ribeiro 2007), or four
weeks (Boulet 1994; Pornsuriyasak 2005), or low dose ICS for
eight weeks (Rytilä 2008). These studies differed in their eligibility
criteria. Participants had cough for at least three weeks (Ponsioen
2005 subacute and chronic cough participants only), more than
three weeks following an URTI (Pornsuriyasak 2005), more than
four weeks (Boulet 1994), or at least eight weeks (Ribeiro 2007;
Rytilä 2008). Participants in Rytilä 2008 also had at least one addi-
tional symptom suggestive of asthma. Smokers were excluded from
three studies (Boulet 1994; Pornsuriyasak 2005; Rytilä 2008).
People with BHR and those taking medications potentially caus-
ing cough were excluded from Boulet 1994 and Pornsuriyasak
2005. Recent steroid use was excluded in Boulet 1994 and Ribeiro
2007, whereas oral corticosteroids were terminated at least one
week prior to entry in Pornsuriyasak 2005. Recent respiratory in-
fection was excluded in Boulet 1994, Ribeiro 2007 and Rytilä
2008, whereas Pornsuriyasak 2005 specifically examined post-
URTI cough. Three studies also excluded GORD (Pornsuriyasak
2005; Ribeiro 2007; Rytilä 2008), and four excluded PND/sinusi-
tis (Ponsioen 2005; Pornsuriyasak 2005 (untreated); Ribeiro 2007;
Rytilä 2008). Cough symptom scores were measured on scales
from 0 to 3 (Rytilä 2008 (morning cough score)), 0 to 6 (Ponsioen
2005 calculated from sum of daytime and nighttime scores), and
0 to 10 (Boulet 1994), and, in the other two studies, were cal-
culated from scores for factors including frequency and sleep in-
terruption (Pornsuriyasak 2005; Ribeiro 2007). Boulet 1994 and
Pornsuriyasak 2005 were small studies with a low or unclear risk of
bias in most categories. Ponsioen 2005, Ribeiro 2007 and Rytilä
2008 were larger studies that achieved a low risk of bias rating
in six of seven domains. The pooled study data demonstrated a
significant standardised mean reduction in cough score of -0.34
(95% CI -0.56 to -0.13; 346 participants; Analysis 1.4; Figure 4).
This result is unlikely to be clinically significant given that this im-
provement correlates to less than the minimal response defined by
Ribeiro 2007 (a reduction of at least two points for each question)
in each of the five included studies. The calculated I2 statistic was
0%. The overall quality of evidence was graded as low due to the
unclear risk of selection bias (Boulet 1994; Pornsuriyasak 2005)
and other bias (Pornsuriyasak 2005) in two included studies, and
a total study population size less than 400.
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Figure 4. Forest plot of comparison: 1 ICS versus Placebo, outcome: 1.4 Mean change in cough score.
VAS for cough
Data for mean change in VAS score were available for only two
studies. Both examined the efficacy of high dose ICS for twoweeks.
Exclusions, of smokers and people with use of medications caus-
ing cough (Chaudhuri 2004), recent steroid use, recent respira-
tory infection, GORD and PND/sinusitis (Ribeiro 2007), varied
between the two studies. The overall risk of bias was low in both
studies. The I2 statistic of 86% calculated from these pooled data
indicated substantial to considerable heterogeneity. For these rea-
sons, pooling was deemed inappropriate for this outcome.
Pulmonary function
Pulmonary function was generally not affected by ICS treatment,
with the exceptionof one study that detected a significant improve-
ment in PEF. None of the three studies that measured BHR found
a significant difference after treatment with ICS versus placebo
(Boulet 1994; Ponsioen 2005; Pornsuriyasak 2005). BHR data
were available as dichotomous data for Ponsioen 2005 (Analysis
1.12), and continuous data for Boulet 1994 (Analysis 1.13), which
prevented pooling of data for this outcome.
Two studies found no significant improvement in FEV1 follow-
ing treatment with ICS (Ponsioen 2005; Pornsuriyasak 2005),
with data available for only one of these studies (Ponsioen 2005;
Analysis 1.14). The one study that reported FVC and FEF25−75%
demonstrated no significant improvement in either outcome
(Pornsuriyasak 2005). Improvement in PEF varied, with one study
finding a significant treatment effect for morning PEF after four
weeks and eight weeks, and evening PEF after eight weeks (Rytilä
2008), and the other study finding no significant effect (Evald
1989). Insufficient data were available to produce a meta-analysis
for change in pulmonary function.
Complications of cough
Requirement for additional use of medication was the only com-
plication of cough shown to be reduced by ICS treatment. Specif-
ically, requirement for additional medication after the treatment
period (Ponsioen 2005; Analysis 1.15), and use of reliever med-
ication (Rytilä 2008), were significantly decreased. Three studies
that examined frequency of nocturnal awakenings noted no signif-
icant reduction with ICS treatment (Evald 1989; Ponsioen 2005;
Ribeiro 2007), and data were reported for only one study (Ribeiro
2007; Analysis 1.16). Ponsioen 2005 found no significant decrease
in days off work. Pooling was not possible due to inadequate re-
porting of data.
Biomarkers of inflammation
Sputum total and differential cell counts
Sputum total and differential cell counts were not significantly af-
fected by ICS (Chaudhuri 2004; Pizzichini 1999), with the excep-
tion of eosinophils, which were significantly reduced in one study
(Rytilä 2008), but not in two others (Chaudhuri 2004; Pizzichini
1999). Where the final diagnosis was known (Chaudhuri 2004),
subgroup analysis showed a significant improvement in sputum
eosinophilia among participants with cough attributable to CVA
(-4.60%; 95% CI -7.10 to -2.10; Analysis 1.21).
Inflammatory mediators
ECPwas the only inflammatory mediator significantly reduced by
ICS (Chaudhuri 2004; Rytilä 2008), but this was not seen in all
studies (Pizzichini 1999). Subgroup analysis by cough aetiology
in Chaudhuri 2004 (Analysis 1.18) revealed no significant effects.
No study showed significant improvement in levels of other spu-
tum biomarkers of inflammation including interleukin-8 (IL-
8) (Chaudhuri 2004; Pizzichini 1999), cysteinyl leukotriene
(Cys-LT), leukotriene B4 (LTB4), myeloperoxidase (MPO) and
prostaglandin E2 (PGE2), tumour necrosis factor alpha (TNF-
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α) (Chaudhuri 2004), or fibrinogen, albumin, substance P and
bronchial epithelial cells (Pizzichini 1999). When analysed by fi-
nal diagnosis in Chaudhuri 2004, participants with bronchiecta-
sis showed a significant increase in MPO (133.5 µg/mL; 95% CI
27.0 to 239.9; Analysis 1.23) and a significant reduction in IL-8
(-74.7 ng/mL; 95% CI -146.3 to -3.1; Analysis 1.27).
Insufficient data prevented meta-analysis for these outcomes.
Exhaled gases
In Chaudhuri 2004, ICS treatment resulted in significant reduc-
tions in eNO overall (-2.1 ppb; 95% CI -3.6 to -0.6), and specifi-
cally among participants with cough attributable to GORD (-3.1
ppb; 95% CI -5.8 to -0.5) and CVA (-3.3 ppb; 95% CI -6.5 to -
0.2) (Analysis 1.29). Carbon monoxide was significantly reduced
overall (-0.3 ppm; 95%CI -0.6 to -0.0), but not for any individual
subgroup of cough aetiology (Analysis 1.30).
Adverse effects of intervention
Treatment with ICS was not associated with a significant increase
in total adverse effects compared with placebo in the studies that
reported this outcome (Pizzichini 1999; Ponsioen 2005; Ribeiro
2007; Rytilä 2008). In terms of specific adverse effects, no signif-
icant differences were found in hoarseness, sore throat, oral can-
didiasis (Ponsioen 2005; Ribeiro 2007), or severe adverse effects
(Ponsioen 2005; Ribeiro 2007; Rytilä 2008). More commonly re-
ported adverse effects included hoarseness, sore throat, dry mouth
and headache.
Combined results
The proportion of participants with adverse effects was reported
in four studies (Pizzichini 1999; Ponsioen 2005; Ribeiro 2007;
Rytilä 2008), allowingmeta-analysis for this outcome. These stud-
ies all had a low risk of bias in six of the seven domains assessed.
These trials examined a heterogeneous population comprising par-
ticipants with cough for at least two weeks (Pornsuriyasak 2005),
to more than one year (Pizzichini 1999). Studies also varied in
terms of exclusion of smokers (Pizzichini 1999; Rytilä 2008),
people with BHR (Pizzichini 1999), medications causing cough
(Pizzichini 1999; Ponsioen 2005), recent steroid use (Ponsioen
2005; Ribeiro 2007), recent respiratory infection (Pizzichini 1999;
Ribeiro 2007; Rytilä 2008), and people with GORD (Pizzichini
1999 (untreated); Ribeiro 2007; Rytilä 2008). People with PND/
sinusitis were excluded from three of these studies (Ponsioen 2005;
Ribeiro 2007; Rytilä 2008), with adequately treated participants
only being permitted in one study (Pizzichini 1999). It was un-
clear whether use of medications causing cough, recent steroid use
or recent respiratory infection were among the exclusion criteria
for Ponsioen 2005. Three studies were of high dose ICS for two
weeks (Pizzichini 1999; Ponsioen 2005; Ribeiro 2007), with one
study examining low dose ICS for eight weeks via either MDI
or DPI (Rytilä 2008). No individual study reported a significant
increase in adverse effects, and the pooled effect estimate was also
not statistically significant (OR 1.67; 95% CI 0.92 to 3.04; 381
participants; Analysis 1.31; Figure 5). The calculated I2 statistic of
0% indicated that heterogeneity in study populations, interven-
tions and measured outcomes was probably not important. The
quality of evidence was downgraded to moderate due to the wide
confidence interval.
Figure 5. Forest plot of comparison: 1 ICS versus Placebo, outcome: 1.31 Proportion with adverse effects.
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Pooling of results was not appropriate for the outcomes of specific
and severe adverse effects due to these events being infrequent, or
not present in studies (Analysis 1.32; Analysis 1.33).
D I S C U S S I O N
Summary of main results
Eight studies examined the efficacy of ICS in people with suba-
cute and chronic cough associated with frequently undiagnosed,
as well as unexplained, causes. Studies were heterogeneous in their
populations, interventions, outcome measures, reporting and re-
sults (Figure 2). A significant reduction in cough severity was ob-
served in one cross-over trial and one parallel group trial. Please
see Summary of findings for the main comparison for details of
the main findings.
For the primary outcome of clinical cure or significant improve-
ment (more than 70% reduction in cough severity measure) at fol-
low up (clinical success), data were available for only three studies
that were too heterogeneous in their study characteristics to allow
meta-analysis.
Meta-analysis for the outcomes of proportionwithmore than 50%
improvement and clinical cure was not possible due to heterogene-
ity in study design.
The mean decrease in cough score following ICS treatment was
0.34 standard deviations lower compared to placebo (95% CI -
0.56 to -0.13; 346 participants) following ICS, though the quality
of this evidence was low. Meta-analysis was not possible for the
outcome of mean change in VAS score due to heterogeneity in
study characteristics.
In terms of pulmonary function, there was no improvement in
BHR in the three studies of high dose short duration ICS that
examined this outcome. Two studies demonstrated no significant
improvement in spirometry. PEF significantly improved in one
study but not in another.
Treatment with ICS was associated with a reduction in additional
medication requirement. No effect on nocturnal awakenings, or
days off work, was found in three studies, and one study, respec-
tively.
Significant improvements in sputum eosinophils were demon-
strated in one study but not in two others. ECP was significantly
reduced by ICS in two out of three studies. Sputum total cell
counts, neutrophils and lymphocytes were not improved in two
studies. No study showed improvement in levels of other sputum
biomarkers. Exhaled NO and CO significantly decreased in one
study.
While themoderate quality evidence demonstrated no statistically
significant increase in adverse effects, the potential benefits of ICS
therapy need to be considered in the light of these possible harms.
Impact of heterogeneity of studies
The conflicting findings probably result from significant diversity
in study design, participants, interventions and outcome measures
between studies.
Study design
Cross-over trials of persistent cough increase risk of bias due to
the potential for a prolonged carry-over effect, which is difficult
to control for with a washout period. For instance, Boulet 1994
attributed the reduction in cough symptoms in four participants
who received placebo during the second treatment period to the
persistent effect of beclomethasone from the first period.However,
Chaudhuri 2004 found no carry-over effect.
Participants
Inconsistent study findings are most likely largely attributable to
heterogeneity in study populations. This was described as a limi-
tation in Rytilä 2008. Heterogeneity among review participants is
explained by the diversity in aetiology of cough due to the inher-
ently unexplained nature of the condition, as well as differences
in sample sizes, study settings and eligibility criteria.
Sample sizes
None of the smaller studies, i.e. with 50 participants or fewer,
found ICS to be effective (Boulet 1994; Evald 1989; Pizzichini
1999; Pornsuriyasak 2005). This is likely to reflect the fact that
these had inadequate statistical power to detect a significant treat-
ment effect. Inadequate sample size was recognised as a limitation
in two study reports (Pornsuriyasak 2005; Rytilä 2008).
Setting
Differences in study settings may have influenced the types of par-
ticipants recruited, which would have contributed to heterogene-
ity in study populations, and, in turn, to inconsistencies in the effi-
cacy of ICS. None of the studies that recruited participants exclu-
sively from hospital or specialty clinics found ICS to be beneficial
(Boulet 1994; Evald 1989; Pornsuriyasak 2005; Rytilä 2008). As
Rytilä 2008 recognised, only participants with severe symptoms
were likely to be included in such a setting. While Ponsioen 2005
found no correlation between baseline cough severity and treat-
ment effect, it is possible that people presenting to specialist clinics
may have a cough that ismore refractory to treatment for other rea-
sons, for example if previous primary care interventions have been
unsuccessful. Ponsioen 2005, however, who recruited exclusively
from primary care practices, did not find a significant treatment
effect once people with acute cough were excluded. Studies of par-
ticipants recruited from a combination of community and hospital
settings found ICS to be effective in some instances (Chaudhuri
2004; Ribeiro 2007), but not others (Pizzichini 1999).
Cough duration
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Some authors suggested that people with cough of shorter dura-
tion may be more responsive to ICS (Chaudhuri 2004), and a cor-
relation between cough duration and treatment response was seen
in Ribeiro 2007.While this does not appear to be supported by the
results of this review, confounding factors are probably present.
ICS was not effective in reducing cough among trials of people
with predominantly subacute cough. While Ponsioen 2005 noted
a significant improvement following ICS among participants with
cough for at least two weeks duration, the treatment effect was not
significant once 31 participants with acute cough were excluded
from the analysis (mean cough duration 5.5 weeks (SD 3.2)).
Further, Pornsuriyasak 2005 found no significant treatment effect
among participants with post-URTI cough of greater than three
weeks duration (mean 5.93 weeks (SD 1.94)), however this may
bemore of a reflection of the differing aetiology of subacute cough.
None of the studies of people with predominantly chronic cough
found a significant treatment effect (Boulet 1994; Evald 1989),
however, confounding factors were probably present. For instance,
Evald 1989 suggested that the significant period effect observed
suggested that some participants may have had infectious cough,
which is not responsive to ICS (Frank 1985).
There was no clear relationship between cough duration and ICS
efficacy in the studies that included only chronic cough partici-
pants. ICS reduced cough severity in studies of people with cough
for a mean 44.6 weeks (SD 86.2) (Ribeiro 2007), and mean 16.2
years (SD 16.1) (Chaudhuri 2004), but not in two other studies
where mean cough duration was 9.8 years (95% CI 5.3 to 14.2)
and 11.8 years (95% CI 4.6 to 19.2) for ICS and placebo groups
respectively (Pizzichini 1999), and not specified (Rytilä 2008).
Rytilä 2008 suggested the inconsistency in response to ICS ob-
served in their study might be partially attributable to “high vari-
ability of symptoms with asymptomatic periods”.
Age
Cough aetiology and management differs between children and
adults (Chang 2005). Hence, the inclusion of children older than
15 years in Evald 1989 may have contributed to the poor response
to ICS in this study, given that ICSmay not be effective in children
who have had cough for more than three weeks (Tomerak 2009).
Bronchial hyper-responsiveness
The relationship between BHR and the steroid-responsive condi-
tion of CVA may explain why ICS was effective only in studies
that did not exclude people with BHR.
Bronchial provocation testing is recommended for the evaluation
of cough in people with suspected CVA who have had a non-
diagnostic physical examination and spirometry (Irwin 2006a).
Due to its negative predictive value of nearly 100%, a negative test
effectively excludes CVA (Madison 2010). The positive predictive
value of bronchial provocation testing is lower (60% to 80%),
and hence the presence of BHR does not necessarily mean the
patient has asthma. Therefore, response to anti-asthma treatment
is required to diagnose CVA (Madison 2010).
Both studies that found ICS to be effective did not exclude partici-
pants with BHR. Ribeiro 2007 noted a significant treatment effect
among participants with baseline mean ± SD PD20 measurements
of 5.35 mg ± 3.2 mg and 4.56 mg ± 3.7 mg for treatment and
control groups, respectively. It should be noted that the significant
difference between these groups at baseline was considered to be
unimportant given that the PD20 values of participants with BHR
were higher than those typically seen in asthma (usually less than
4 mg/mL), and, therefore, could be consistent with hyper-respon-
siveness found in healthy people (Ribeiro 2007). This significantly
positive parallel group trial of participants with predominantly
chronic cough with cough-variant asthma contributed the major-
ity of statistical heterogeneity for each of the outcomes measuring
of proportion of patients with improvement. While Chaudhuri
2004 did not report baseline BHR data, participants with CVA
showed the greatest improvement in VAS. CVA was diagnosed
based primarily on response to ICS and short-acting β2-agonist
after the treatment period, however, bronchial challenge testing
was also utilised to help establish a diagnosis. Therefore, this sub-
group probably also had BHR.
Furthermore, ICS were not effective in both Boulet 1994 and
Pizzichini 1999, where people with baseline BHR were excluded,
and in Pornsuriyasak 2005, where only four people with a positive
bronchial provocation test were included (4/30), three of whom
had only mild BHR.
In contrast, three studies that included participants with BHR
found no effect (Evald 1989; Ponsioen 2005; Rytilä 2008). BHR
was identified in 30% of participants (3/10 tested) in Evald 1989,
36% of participants (34/94 tested) in Ponsioen 2005, and 50%
(35/70 tested) of participants in Rytilä 2008. Failure to identify
a response in these studies could be due to other confounding
factors, for example low dose of ICS (Evald 1989; Rytilä 2008).
Also, given that the methacholine inhalation challenge has been
shown to be falsely positive in 22% of people with chronic cough
(Irwin 1990), it is possible that these studies included people with
BHR, but without CVA.
Two studies specifically investigated the relationship between base-
line BHR and response to ICS, with neither finding a correlation
(Ribeiro 2007; Rytilä 2008). This, however, was assessed in terms
of total symptom score (not necessarily cough) in Rytilä 2008.
Ribeiro 2007 noted that BHR increased the odds of resolution of
cough with ICS treatment (OR 9.8, 95% CI 1.09 to 88.23). The
trialists attributed the higher number of participants with both
BHR and response to ICS than in other studies to different study
eligibility criteria and the high dose of ICS used.
It should be recognised that the absence of BHR does not exclude
a steroid-responsive cough (Morice 2006), and this is consistent
with the finding that improvement in symptom scores was not
always restricted to people with BHR (Rytilä 2008). For exam-
ple, these people may have had eosinophilic bronchitis which is
responsive to ICS but does not involve BHR (Irwin 2006a).
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Airway inflammation
Differences in airway inflammation among participants may have
contributed to inconsistencies in responses to ICS. While there
was no clear evidence as to whether sputum eosinophilia improved
response, participants without sputum eosinophilia showed a poor
response.
In other airway inflammatory conditions, sputum eosinophilia
seems to predict steroid responsiveness (Chanez 1997; Kitaguchi
2012; Pizzichini 1998), whereas participants with neutrophilic
inflammation may be less likely to respond (Green 2002;
Pavord 1999). Previous studies have noted a relationship be-
tween eosinophilia and steroid responsiveness among people with
chronic cough (Gibson 1989; Gibson 1998), and symptoms sug-
gestive of asthma (Rytilä 2000). Further, ICS have been shown to
reduce eosinophilic airway inflammation in eosinophilic bronchi-
tis (Gibson 1995; Xu 2011).
Among the included studies that performed baseline sputum anal-
ysis, populations without sputum eosinophilia showed a poor re-
sponse to ICS. Boulet 1994 observed no response among par-
ticipants with predominantly mononuclear inflammation. Non-
eosinophilic, predominantly neutrophilic airway inflammation
was suggested as a cause for the very modest response achieved in
Chaudhuri 2004 and the lack of effect in Pizzichini 1999. ICS did
not significantly reduce sputum eosinophil counts in either study,
whereas ECP, an indirect marker of eosinophil activity, was re-
duced in Chaudhuri 2004, but not in Pizzichini 1999. Rytilä 2008
also found no significant improvements in cough scores among a
group of participants where approximately one-fifth had sputum
eosinophilia, however, the authors suggested that higher rates of
eosinophilic inflammation may have been detected with repeated
sputummeasurements. While Evald 1989 did not investigate spu-
tum inflammation, participants in this trial did not respond to
ICS and had a low incidence of blood eosinophilia, which is a less
sensitive marker of airway eosinophilia (Pizzichini 1997).
Despite this, no individual included study found that sputum
eosinophilia predicted the response to ICS. Rytilä 2008 found no
correlation between participants with baseline eosinophilia and a
response to ICS. In one report of a subset of included patients,
Chaudhuri 2004 found that neither sputum eosinophils nor neu-
trophils predicted ICS responsiveness, however, a normal sputum
eosinophil count was associated with a poorer response. While
bronchial biopsies were not histologically different between the
steroid responders and non-responders in Boulet 1994, the au-
thors suggested that insufficient dose or duration of treatmentmay
have limited the trial’s ability to detect an effect.
ICS showedmixed effects on sputum eosinophils and ECP among
included studies, and this was perhaps also due to differences in
inflammatory patterns of participants.
Sputum inflammation was not investigated in three studies
(Ponsioen 2005; Pornsuriyasak 2005; Ribeiro 2007).
Smoking
There was no clear trend in response to ICS among studies that
did and did not exclude smokers; however, other evidence sug-
gests that smoking reduces efficacy of ICS in cough. For exam-
ple, ICS were more effective in non-smokers than smokers when
directly compared in Ponsioen 2005, with the authors suggesting
that this was because non-smokers have a greater baseline cough-
reflex sensitivity in comparison to smokers (Dicpinigaitis 2003).
Furthermore, studies have shown that ICS are ineffective in re-
ducing smoking-related neutrophilic airway inflammation (Cox
1999).
Recent respiratory infection
ICS may not be effective for the treatment of post-URTI cough.
Both studies that found ICS to be effective excluded people with
recent respiratory infection (Chaudhuri 2004; Ribeiro 2007). Fur-
ther, ICS were not effective in the one study that specifically ex-
amined post-URTI cough (Pornsuriyasak 2005), nor in the other
study of predominantly subacute cough (Ponsioen 2005), how-
ever, this perceived relationship may have been confounded by
other factors.
Recent steroid use
The impact of recent steroid use on efficacy of ICS remains un-
certain. People with recent steroid use were excluded from both
of the studies that found ICS to be successful (Chaudhuri 2004;
Ribeiro 2007). In the studies that did not exclude people with
previous steroid use, ICS were not effective (Pornsuriyasak 2005;
Rytilä 2008). This result may, however, have been confounded
by other study design factors. In contrast, several studies that ex-
cluded people with recent steroid use also found no effect (Boulet
1994; Evald 1989; Pizzichini 1999). It was unclear whether these
people were excluded from the Ponsioen 2005 trial, which did not
find ICS to be beneficial.
Several authors specifically investigated this relationship.
Chaudhuri 2004 excluded people with inhaled or oral steroid use
in the previous three weeks, but found no difference in response
amongparticipantswhohad received a prior course of ICS.Ribeiro
2007 also noted that participants who had previously received cor-
ticosteroids showed no significant difference in response to ICS.
In an earlier report, however, Ribeiro 2007 noted that “drug use in
recent weeks ormonths”was significantly lower in responders than
non-responders to ICS, although whether this related to steroid
use was not clear.
Medications causing cough
There were no clear trends in the results of studies that did and did
not exclude people taking medications potentially causing cough.
Extrapulmonary causes of cough
There were no notable differences in the efficacy of ICS amongst
trials that did and did not exclude cough potentially attributable
to extrapulmonary causes such as GORD and PND.
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Interventions
Variation in the interventions used may also have contributed to
the observed inconsistencies between studies.
Dose
Both of the studies that showed a significant treatment effect used
a budesonide equivalent dose of at least 1200 µg/day (Chaudhuri
2004; Ribeiro 2007), whereas ICS was not effective in reducing
cough scores in either of the studies that used a low dose (Evald
1989; Rytilä 2008). In a recent Cochrane systematic review of ICS
for non-specific chronic cough in children, Tomerak 2009 also
found a significant improvement in the one study that used high
dose ICS, but not in the study using low dose ICS.
The apparent reduced efficacy of low dose ICS, however, may
be an artefact of confounding factors. For instance, Evald 1989
used only a short duration of treatment, and participants in Rytilä
2008 were required to have an additional symptom in addition
to cough. Furthermore, Ponsioen 2005 described no dose-effect
relationship.
Treatment duration
While longer duration of treatment may increase the observed
efficacy of ICS, the two studies that found ICS to be effective used
a treatment period of only two weeks (Chaudhuri 2004; Ribeiro
2007). Other studies using high dose ICS for four weeks did not
necessarily produce a response to ICS (Boulet 1994; Pornsuriyasak
2005).
Dosage regimen
Twice-daily dosing was most common, and was used by four stud-
ies that found no treatment effect (Evald 1989; Pizzichini 1999;
Ponsioen 2005; Pornsuriyasak 2005), and one of the studies that
found ICS to be effective (Chaudhuri 2004). The second study
that identified a treatment effect used thrice (three times) daily
dosing (Ribeiro 2007). Once-daily dosing was not effective in re-
ducing cough scores in Rytilä 2008. Studies of the efficacy of once-
daily dosing of ICS in asthma have given conflicting results (Boulet
2004). Dosing four-times daily did not produce a treatment ef-
fect (Boulet 1994), perhaps because of the inverse relationship
between dose frequency and compliance (Boulet 2004; Claxton
2001). Compliance was reasonably high in studies that used twice-
daily and once-daily dosing (Ponsioen 2005; Rytilä 2008).
Studies that found a treatment effect used two or six puffs a day
(Chaudhuri 2004; Ribeiro 2007). Studies with eight puffs a day
were not effective (Boulet 1994; Evald 1989; Pornsuriyasak 2005).
This may also have been related to compliance or inhalation tech-
nique.
Type of ICS
While differences in pharmacodynamic and pharmacokinetic
properties of different types of ICS can lead to differences in effi-
cacy and safety (Derendorf 2006), there were no clear differences
between the types of ICS used in studies that did, and did not,
demonstrate a significant treatment effect.
Administration
Although the use of different inhalation devices can have impli-
cations for inhalation technique and compliance, and in turn ef-
ficacy (Barnes 1998), the type of inhalation device used did not
seem to influence whether or not a treatment effect was observed.
Outcomes
The use of different outcome measures between studies also lim-
ited the validity of comparing the studies, and may have con-
founded the observed relationships between ICS and change in
cough severity. No study reported objective cough severity mea-
sures, which is common in cough treatment research (Leconte
2011).While all studies used some form of cough score assessed by
the participant, these subjective scores have largely not been vali-
dated (Leconte 2011), as recognised in one report (Pornsuriyasak
2005). Only one study report described validation of the cough
score used against objective measures of cough frequency and in-
tensity (Ponsioen 2005). Additionally, the types of cough scores
used lack consistency between trials, thereby limiting the general-
isability of results. For these reasons, the clinical importance of a
reduction in a subjective cough severity measure that has not been
validated, or used in other studies, is unclear.
Overall completeness and applicability of
evidence
While we identified many relevant, high quality RCTs of ICS for
subacute and chronic cough, our ability to address all primary and
secondary outcomes was limited by differences in study design
and reporting. Variation in eligibility criteria, interventions and
outcome measures made pooling of data inappropriate for several
outcomes where data were available. Additionally, data pertaining
to the primary outcome were available for only three studies, and
most secondary outcomes were assessed by only a few studies. For
these reasons, a narrative review of findings, rather than statistical
pooling and meta-analysis, was necessary for most outcomes.
Conversely, this substantial heterogeneity probably increases the
external validity of the conclusions drawn. The wide variety of
people who participated in these studies most probably reflects
the diversity of people with this common, and inherently diffi-
cult to define, clinical problem. Similarly, the varied interventions
used probably replicate variations in clinical practice. Addition-
ally, while data for some of the outcomes were limited, a range
of clinically important outcomes were assessed across the studies.
Therefore, it is likely that all relevant types of participants, inter-
ventions and outcomes have been investigated.
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Quality of the evidence
We assessed the effects of ICS in people with subacute and chronic
cough through narrative review and limited meta-analysis of eight
studies including 570 participants. The robustness of the conclu-
sions we could draw was restricted by methodological limitations,
including the cross-over design of one trial, heterogeneity in study
characteristics, and inadequate reporting of data. These factors
limited statistical pooling of data, and probably also contributed
to the inconsistencies in study findings, with two trials finding
ICS to be beneficial, and six trials finding ICS to be largely inef-
fective. While comparing the number of positive studies with the
number of negative studies through narrative review allowed us
to determine whether there is any evidence for an effect of ICS,
accurate quantification of the extent and direction of effect was
not possible with the limited data available.
The quality of evidence for each pooled outcome measure was de-
termined using GRADE criteria. Narrative evidence for the pri-
mary outcome was of low quality, with evidence downgraded on
the basis of the unclear risk of selection bias (Boulet 1994) and
reporting bias (Ponsioen 2005; Ribeiro 2007) in included studies,
and the small number of recorded events. Evidence for the finding
that ICS increased the proportion achieving a greater than 50%
improvement in cough severity measure was downgraded to low
quality due to the unclear risk of selection bias in one included
study (Boulet 1994) and the small number of recorded events.
The unclear risk of selection (Boulet 1994) and reporting bias in
included studies (Ponsioen 2005; Ribeiro 2007; Rytilä 2008), and
the small number of events for the proportion of participants with
clinical cure at follow up resulted in a low quality grading for this
narrative evidence. Evidence for mean change in cough score was
deemed to be low quality because of unclear risk of selection bias
(Boulet 1994; Pornsuriyasak 2005) and other bias (Pornsuriyasak
2005) in included studies, and a total population size that was
less than 400. Moderate quality evidence was used to assess the
proportion that experienced adverse effects of treatment, with ev-
idence quality downgraded due to the wide confidence interval.
Potential biases in the review process
Several methodological strengths minimised the risk of bias in the
review process. Explicit methodology was defined a priori in a
published protocol. Comprehensive, systematic search strategies
and independent study selection by two authors maximised the
likelihood of identifying all relevant studies. Independent data
extraction by two authors also reduced the risk of error in data
collection.
Limitations of the review that may have introduced bias arose
from inconsistent reporting of data in the trial reports. Despite
attempts to contact study authors, not all the required data could
be obtained. Inconsistent reporting and missing data limited our
ability to pool data through meta-analysis for the majority of out-
comes. Hence, it is possible that the effects of ICS could have
been underestimated, since the results of individual studies that
lacked statistical power could not be combined. Narrative review
in the place of statistical pooling of data can introduce bias where
statistical significance is used to define studies showing an effect,
and does not take into account the weighting of studies (Higgins
2011). This post hoc approach was also a limitation of subgroup
analysis, for which we were unable to perform tests for interaction.
Agreements and disagreements with other
studies or reviews
This is the first systematic review of ICS for subacute and chronic
cough in adults. While there are numerous narrative reviews of
management strategies for subacute and chronic cough in general,
many of these focus primarily on cause-directed treatment (e.g.
Chummun 2011), or antitussive therapy (e.g. Bolser 2010). Pre-
vious reviews of ICS for cough have been largely limited to people
with CVA (Antoniu 2007; Cazzola 2008). A recent systematic re-
view of pharmacological and non-pharmacological interventions
for cough in adults identified four of the same trials as our review
(Chaudhuri 2004; Evald 1989;Molassiotis 2010; Pizzichini 1999;
Ribeiro 2007), but did not draw specific conclusions about ICS
for adults with subacute and chronic cough.
This Cochrane review provides weak evidence in support of some
current clinical guidelines. These guidelines recommend the sys-
tematic exclusion and treatment of common causes of subacute
and chronic cough, which, in some instances, includes treatment
with ICS.
Subacute cough is most often attributed to postinfectious cough,
which can be treated with the inhaled anticholinergic drug iprat-
ropium or failing this, ICS (Irwin 2006a). While no clear conclu-
sions could be drawn, the results of this review suggest that ICS
may not be beneficial in these people, especially given that one
study that specifically examined post-URTI cough showed that
ICS were not beneficial (Pornsuriyasak 2005). Subacute cough in
the absence of an obvious infectious cause is managed in the same
way as chronic cough (Irwin 2006a).
After examination, chest X-ray and spirometry, people with
chronic cough with no identifiable cause should undergo inves-
tigation and treatment for the most common causes of chronic
cough - asthma, PND and GORD (Irwin 2006a). ICS are specif-
ically indicated in several instances.
Current Australian cough guidelines recommend that adults with
non-specific or refractory cough receive an empirical trial of ICS
therapy (Gibson 2010). The strength of this recommendation is
classified as strong according to the GRADE approach, which
considers not only quality of evidence but also balance between
desirable and undesirable effects, values and preferences and costs
(Guyatt 2008), however, no studies are specifically cited in these
guidelines. Given that ICS seem to benefit some people, the find-
ings of our review provide weak evidence in support of this rec-
ommendation.
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Several international guidelines also recommend ICS for CVA
(Irwin 2006a; Morice 2004; Morice 2006), and people with a
positive bronchial provocation test (Morice 2006). Our review
identified only one study that specifically addressed CVA, which
noted a significantmean reduction inVAS score of 1.4 cm (95%CI
-0.0 to 2.7) after two weeks (Chaudhuri 2004). Given that all the
studies that showed ICS to be effective included participants with
baseline BHR, it is possible that many participants who responded
did have CVA.
ICS are also recommended for non-asthmatic eosinophilic bron-
chitis (Irwin 2006a;Morice 2004;Morice 2006), and atopic cough
(Morice 2006). No randomised controlled trials that specifically
examined these interventions met the inclusion criteria for this
review, and subgroup analysis could not be performed for the
small number of participants with eosinophilic bronchitis who
were identified in one study (Chaudhuri 2004).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This Cochrane review provides the first comprehensive system-
atic review of the evidence for inhaled corticosteroids (ICS) for
subacute and chronic cough in adults. Overall, the studies were
highly heterogeneous and the results were inconsistent. One par-
allel group trial of predominantly chronic cough with CVA which
identified a significant treatment effect contributed the major-
ity of statistical heterogeneity for several outcomes. The factors
that predict response to ICS could not be fully determined. A
trial of ICS should only be considered in adults after thorough
work-up including chest X-ray and consideration of spirometry
and other appropriate investigations, in accordance with interna-
tional cough guidelines (Gibson 2010; Irwin 2006a;Morice 2004;
Morice 2006).
Implications for research
This systematic review has demonstrated the need for greater con-
sistency in study design, participants, interventions, outcomemea-
sures and reporting in future trials of ICS for subacute and chronic
cough in adults.
Study design
Cross-over trials should not be used because of the risk of a sig-
nificant carry-over effect. Assessing time taken to achieve clini-
cal cure or significant improvement as well as factors that predict
response to treatment would also be useful. This should include
further evaluation of eNO, which has shown promise as a surro-
gate marker for airway eosinophilia and steroid responsive cough
(Taylor 2006). A follow up period sufficient to investigate possi-
ble carry-over effects, as well as cough recurrence, after cessation
of ICS therapy has also been recommended previously (Chang
2011).
Participants
More clearly defined study populations are required for future
studies (Chang 2011). Consistency in eligibility criteria is required
tominimise heterogeneity in study populations and, in turn, to al-
lowmore meaningful comparisons to be made (Molassiotis 2010).
This could include using standardised guidelines requiring history
and examination, spirometry and chest X-ray to exclude people
with more readily identifiable and treatable causes in order to fo-
cus on those with unexplained cough. It would be most useful for
this to reflect diagnostic protocols used in clinical practice in or-
der to select a clinically relevant patient population. Medications
causing cough and untreated extrapulmonary disease (e.g. gastro-
oesophageal reflux disease, postnasal drip) should be excluded as
causes for cough. Smoking status, recent steroid use and recent res-
piratory infection should also be recorded. Determining the final
cause for cough, as done in some included studies (Boulet 1994;
Chaudhuri 2004), would also help elucidate the peoplemost likely
to respond to ICS.
Interventions
The results of this review suggest that high dose ICS for two weeks
may be an appropriate intervention where a trial of ICS is con-
sidered, however, further investigation of the optimal duration of
therapy would be useful (Chang 2011). Prolonged duration of
ICS treatment for more than eight weeks could be studied. Using
comparable interventions across trials would also facilitate more
meaningful pooling of study data.
Outcomes
Consistency in cough severity measures is integral for allowing
comparison of results between studies. Cough severity should be
the primary outcome, and should be assessed by validated sub-
jective and objective measures (Chang 2011; Molassiotis 2010).
While objective cough measures provide evidence of frequency
and intensity, subjective cough scores better reflect participants’
perceptions of the cough and quality of life. Assessment of both
types of outcome measures would, therefore, be very useful in
determining whether ICS treatment yields clinically important
outcomes (Chang 2011; Leconte 2011; Molassiotis 2010). A re-
cent systematic review on cough assessment endorsed the Leicester
Cough Questionnaire (LCQ) and Cough Quality of Life Ques-
tionnaire (CQLQ) instruments as validated quality of life scores
(Leconte 2011). Visual analogue scales are also useful for assess-
ing people’s perception of cough severity, despite not necessarily
correlating with either objective or quality-of-life scores. While
cough frequency can also be used to monitor treatment response,
further validation of available techniques has been recommended
(Leconte 2011). Determining the minimal clinically important
difference in these outcome measures is also integral to defining
the practical benefit of any identified treatment effects.
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Reporting
Inconsistent reporting of outcomes needs be addressed in future
research. Thresholds for defining clinically significant improve-
ments in cough severity measurements (e.g. improvement of more
than 70%) should also be determined a priori and reported (Chang
2011). For continuous outcomes, reporting data, even if they are
not statistically significant, would be useful for future comparison
between studies, as would including data for all time points mea-
sured. Ideally, dichotomous outcomes should be reported as the
number of events, non-events and participants in each group; and
continuous outcomes should be reported in terms of the mean
difference, standard deviation and number of participants for each
group (Higgins 2011).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boulet 1994
Methods Design: cross-over, no washout, first period data available.
Randomisation: yes, method not reported.
Blinding: double blind.
Withdrawals: none.
Participants Setting: single-centre study, Laval Hospital clinic (Canada)
Number screened: not reported.
Number eligible: 19.
Number randomised: 14.
Number in treatment group: 14 (cross-over).
Number in control group: 14 (cross-over).
Number of withdrawals: 0.
Number completing trial: 14.
Sex: 4 M, 15 F (eligible population).
Age: 25 58 years (eligible population).
Cough duration: mean 3.8 years.
Inclusion criteria: dry cough for > 4 weeks, normal airway response to methacholine
(PC20, the provacative concentration of methacholine inducing a 20% decrease in FEV1
being 20 mg/mL or more), normal chest examination and radiograph
Exclusion criteria: use of a medication known to induce chronic cough (e.g. angiotensin-
converting enzyme (ACE) inhibitors, beta-blockers), inhaled or oral steroid intake within
the preceding 3 months, evidence of respiratory infection in the previous 4 weeks, smok-
ing within the preceding 2 years, past or present history of asthma, chronic bronchitis,
any other chest or systemic disease
Baseline characteristics of treatment:control groups: comparable (cross-over)
Interventions ICS: beclomethasone dipropionate 500 µg, 4 times daily (2000 µg/day)
Control: placebo.
Administration method: MDI with Aerochamber.
Treatment duration: 4 weeks, no washout.
Co-interventions: none.
Outcomes Symptom score.
Other respiratory symptoms.
BHR (methacholine challenge, citric acid challenge).
Notes Main outcome: Mean daily cough scores not significantly different between the two
treatment groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, method not reported.
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Boulet 1994 (Continued)
Allocation concealment (selection bias) Unclear risk Method not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No drop-outs.
Selective reporting (reporting bias) Low risk Number eligible reported, all outcomes re-
ported.
Other bias Low risk First period data available.
Chaudhuri 2004
Methods Design: cross-over, 2 weeks washout between treatments.
Randomisation: yes, computer-generated.
Blinding: double blind.
Withdrawals: stated.
Participants Setting: participants recruited from the community (general practitioner referrals and
newspaper advertisement) and hospital respiratory clinics (Scotland)
Number screened: 120.
Number eligible: 93.
Number randomised: 93.
Number in treatment group: N/A (cross-over).
Number in control group: N/A (cross-over).
Number of withdrawals: 5.
Number completing trial: 88.
Sex: 32 M, 57 F (of 89 with sex recorded).
Age (years): mean 59.0 (SD 12.7).
Cough duration (years): mean 16.2 (SD 16.1).
Inclusion criteria: adults with cough for > 1 year.
Exclusion criteria: evidence of any other lung disease on the basis of history, clinical
examination, chest radiography, and spirometry, treatment with inhaled or oral corticos-
teroids within 3 weeks of inclusion, URTI within 6 weeks of inclusion, ACE inhibitor
treatment, smoking within the past year
Baseline characteristics of treatment:control groups: comparable (cross-over)
Interventions ICS: fluticasone 500 µg twice daily (1000 µg/day).
Control: placebo.
Administration method: DPI (Accuhaler).
Treatment duration: 2 weeks with 2 weeks washout.
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Chaudhuri 2004 (Continued)
Co-interventions: none.
Outcomes VAS (cough severity).
Sputum total and differential cell counts.
Eosinophilic cationic protein (ECP).
Myeloperoxidase (MPO).
Prostaglandin E2 (PGE2).
Leukotriene B4 (LTB4).
Cys-leukotrienes (Cys-LT).
Interleukin-8 (IL-8).
Tumour necrosis factor-alpha (TNF-α).
Exhaled nitric oxide (eNO).
Carbon monoxide (CO).
Notes Main outcome: cough severity and sputum ECP levels were modestly reduced by ICS.
Other sputum biomarker levels were unaltered
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Low risk Randomisation code withheld from inves-
tigators until completion of the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, study medication packed by
central pharmacy and was identical in ap-
pearance and taste
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Five withdrawals with reasons reported,
treatment received by drop-outs not re-
ported
Selective reporting (reporting bias) Low risk Number screened and eligible reported,
reasons for withdrawal reported, all out-
comes reported
Other bias Low risk No carry-over effect observed despite cross-
over trial design with 2 weeks washout
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Evald 1989
Methods Design: cross-over, no washout, first period data available.
Randomisation: method not reported.
Blinding: double blind.
Withdrawals: stated.
Participants Setting: Bispebjerg Hospital chest clinic (Denmark).
Number screened: not reported.
Number eligible: not reported.
Number randomised: 40.
Number in treatment group: N/A (cross-over).
Number in control group: N/A (cross-over).
Number of withdrawals: 13 (7 run-in, 2 first period, 4 second period)
Number completing trial: 31 first period, 27 second period.
Sex: 7 M, 24 F.
Age: 15-64 years.
Cough duration: 3 < 15 days; 6 > 1 month; 10 > 3 months; 9 > 1 year 3 > 5 years
Inclusion criteria: daily dry cough of at least 1 hour duration in more than half of the
last 30 days
Exclusion criteria: obstructive lung function (ratio between the FEV1 and FVC no more
than 70%), significant reversibility after bronchodilating treatment (increase in FEV1
30 min after three inhalations of salbutamol 300 µg and three inhalations ipratropium
60 µg not exceeding 20% or 500 mL), diurnal variation above 20% in morning and
evening PEF during home monitoring for 1 week (calculated at visit 2 after the run-in
period), treatment with anti-asthmatic drugs, abnormal chest X-ray, recent respiratory
infection, other chest disease, pregnancy
Baseline characteristics of treatment:control groups: comparable (cross-over)
Interventions ICS: beclomethasone dipropionate 50 µg 4 puffs twice daily (400 µg/day)
Control: placebo.
Administration method: MDI.
Treatment duration: 2 weeks, no washout.
Co-interventions: none.
Outcomes Patient’s subjective effect of treatment (score).
Degree of cough (including number of days with cough, number of cough attacks a day)
Duration of cough attacks estimated for the whole day.
Spirometry.
PEF.
Number of awakenings each night because of cough.
Duration of insomnia at night because of cough.
Notes Main outcome: no significant treatment effect found for any of the measured variables
Baseline investigations: spirometry, bronchodilator reversibility, bloods, skin prick test,
bronchial provocation test
Run-in period: 1 week
Risk of bias
Bias Authors’ judgement Support for judgement
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Evald 1989 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised, method not reported.
Allocation concealment (selection bias) Unclear risk Method not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 withdrawals during period one, 4 dur-
ing period two; treatment received by drop-
outs not reported
Selective reporting (reporting bias) Unclear risk Number screened and eligible not reported,
scores for participants’ subjective effect of
treatment not reported, reasons for with-
drawal reported
Other bias Low risk First period results described separately;
run-in period.
Pizzichini 1999
Methods Design: parallel group.
Randomisation: yes, computer-generated.
Blinding: double blind.
Withdrawals: stated.
Participants Setting: Firestone Regional Chest and Allergy Clinic and recruited by advertisement
(Canada)
Number screened: 84.
Number eligible: 50.
Number randomised: 50.
Number in treatment group: 21 (completed).
Number in control group: 23 (completed).
Number of withdrawals (treatment:control): 6 (4:2).
Number completing trial (treatment:control): 44 (21:23).
Sex: 16 M, 28 F (completed).
Age: 20-75 years.
Cough duration: 6-19.2 years (completed).
Inclusion criteria: daily bothersome cough for at least 1 year with no other respiratory
symptoms, no evidence of asthma (FEV1 > 70% predicted, FEV1/FVC > 70%, little
response to a bronchodilator), normalmethacholine airway responsiveness (a provocation
concentration of methacholine to cause a fall in FEV1 of 20% (PC20) of > 8 mg/mL)
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Pizzichini 1999 (Continued)
. People with symptomatic gastroesophageal reflux not improved with treatment and
PND who had been previously investigated and treated, and who had no sinusitis on
sinus X-rays were included
Exclusion criteria: smokers, ex-smokers of 6 months or less, indication of respiratory
infection in previous month, history of chronic bronchitis, radiological evidence of chest
disease, other recognised condition or drugs to account for the cough, cardiovascular or
renal disease requiring regular medication, pregnant, received corticosteroids within the
month
Baseline characteristics of treatment:control groups: comparable
Interventions ICS: budesonide 400 µg twice daily (800 µg/day).
Control: placebo.
Administration method: DPI (Turbuhaler).
Treatment duration: 2 weeks.
Co-interventions: none.
Outcomes Questionnaire of cough frequency, cough discomfort (9-point Likert scale)
VAS (cough discomfort in the previous two days).
Spirometry.
Sputum total and differential cell counts, ECP, IL-8, fibrinogen, albumin, substance P
Local side effects (structured questionnaire, oropharyngeal inspection)
Notes Main outcome: treatment did not affect cough or sputummeasurements, perhaps because
the cause was not associated with sputum eosinophilia
Baseline investigations: bloods, allergy skin prick tests.
Study period followed by 2 weeks of open label budesonide.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Low risk Randomisation generated off-site, con-
cealed from investigators, administered by
research nurse
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, identical placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar withdrawal rates for treatment and
control groups.
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Pizzichini 1999 (Continued)
Selective reporting (reporting bias) Unclear risk Several outcomes not reported (change in
cough questionnaire, BHR, spirometry, al-
bumin), number screened and eligible re-
ported, reasons for withdrawals stated
Other bias Low risk Parallel group trial.
Ponsioen 2005
Methods Design: parallel group.
Randomisation: yes, computer-generated.
Blinding: double blind.
Withdrawals: 2.
Participants Setting: community-based primary healthcare centre (6 practices; The Netherlands)
Number screened: 162.
Number eligible: 135.
Number randomised:135.
Total study population (published data):
Number in treatment group: 67 randomised (GSK report), 65 analysed
Number in control group: 68 randomised (GSK report), 68 analysed
Number of withdrawals (treatment:control): 2 (2:0).
Number completing trial (treatment:control): 133 (65:68).
Sex: 47 M, 86 F (analysed population).
Age (years): mean 47.0 (SD 10.1) treatment, mean 43.4 (SD 11.2) control
Cough duration (weeks): mean 4.2 (SD 2.5) treatment, mean 5 (SD 3.7) control; 31
acute cough (< 3 weeks), 89 subacute cough (3-8 weeks), 13 chronic cough (8-17 weeks)
(analysed population)
Subacute and chronic cough participants only (unpublished data):
Number in treatment group: 52.
Number in control group: 50.
Number of withdrawals (treatment:control): 0.
Number completing trial (treatment:control): 102 (52:50).
Sex: 34 M, 68 F.
Age (years): mean 46.7 (SD 10.5) treatment, mean 44.5 (SD 11.2) control
Cough duration (weeks): mean 4.8 (SD 2.5) treatment, mean 6.1 (SD 3.7) control
Inclusion criteria: aged 18-65 years with cough of ≥ 2 weeks duration. Participants
completed a daily diary card for cough (score 0 = absent, 1 = mild, 2 = moderate, 3 =
severe) and other LRT symptoms regarding the previous day and night. Only people
with a night score of ≥1 point and a combined day plus night score of ≥3 points were
included
Exclusion criteria: history of asthma; incidences of self-reported wheeze, pharmacy data
indicating asthma-like symptoms or variability in lung function in the previous year;
current treatment thatmight influence the cough; FEV1 <60%predicted; any concurrent
airway disease (e.g. pneumonia, cancer, tuberculosis, tonsillitis, sinusitis); uncontrolled
systemic disease or pregnancy; people previously randomised for the study
Baseline characteristics of treatment:control groups: comparable
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Ponsioen 2005 (Continued)
Interventions ICS: fluticasone propionate 500 µg twice daily (1000 µg/day)
Control: placebo.
Administration method: MDI via Volumatic spacer.
Treatment duration: 2 weeks.
Co-interventions: no rescue medication allowed, concurrent medication for lower res-
piratory tract symptoms was registered in the diary
Outcomes Symptom score (cough, sputum production, wheezing, shortness of breath and chest
tightness)
Perception of whether coughing had strongly improved, improved, not changed or in-
creased
Spirometry (FEV1, FVC).
BHR (histamine challenge).
Number of awakenings at night.
Number of days off work.
Requirement for additional medication after the treatment period
Hoarseness.
Other adverse events.
(Number cigarettes smoked).
Notes Main outcome: among the total study population, cough score decreased significantly
more in the treatment group, however a favourable effect was only detectable in non-
smokers. ICS was not effective after exclusion of participants with acute cough. Allergy,
FEV1 and BHR at baseline did not predict the efficacy of ICS.
Baseline investigations: bloods (CRP, Phadiatop).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation.
Allocation concealment (selection bias) Low risk Study medication provided by Glaxo-
SmithKline (GSK) according to randomi-
sation list
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, matching placebo inhaler
(GSK report).
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 2 withdrawals (treatment group).
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Ponsioen 2005 (Continued)
Selective reporting (reporting bias) Unclear risk FEF25−75% reported in results but is not de-
scribed as an outcome in methods section,
number screened and eligible reported, rea-
sons for withdrawals stated
Other bias Low risk Compliance measured; parallel group trial.
Pornsuriyasak 2005
Methods Design: parallel group.
Randomisation: yes, method not reported.
Blinding: double blind.
Withdrawals: stated.
Participants Setting: 1200-bed university hospital (Thailand).
Number screened: not reported.
Number eligible: not reported.
Number randomised: 30.
Number in treatment group: 15.
Number in control group: 15.
Number of withdrawals (treatment:control): 4 (1:3).
Number completing trial (treatment:control): 26 (14:12).
Sex: 6 M, 24 F.
Age (years): mean 40.6 (SD 11.8) treatment, mean 38.8 (SD 13.0) control
Cough duration (weeks): mean 5.93 (SD 1.94) treatment, mean 4.66 (SD 2.05) control
Inclusion criteria: consenting, non-smoking adults with persistent post-URTI cough of
> 3 weeks duration; aged > 15 years; normal physical examination; normal CXR; spirom-
etry at baseline: FVC ≥ 80% predicted, FEV1 ≥ 80% predicted, and FEV1/FVC (≥
70% predicted); sinusitis treated appropriately by an Ear, Nose, Throat physician before
entry into the study, if the patient had physical signs and/or an abnormal sinus radio-
graphy. People with a negative methacholine challenge test were randomised, however
three people with a mildly positive bronchial provocation test were included
Exclusion criteria: medical history suggesting asthma; symptoms suggesting gastroe-
sophageal reflux prior to or during post-URTI coughing bouts; history of taking medi-
cation that induces coughing; contraindication to methacholine challenge testing. Initial
treatment with beta2 agonists (inhaled and oral), theophyllines, corticosteroids (oral),
and inhaled anticholinergics were terminated at least 1 week prior to entry into the study
Baseline characteristics of treatment:control groups: comparable
Interventions ICS: budesonide 100 µg, 4 puffs twice daily (800 µg daily).
Control: placebo, 4 puffs twice daily.
Administration method: DPI.
Treatment duration: 4 weeks.
Co-interventions: other medications were allowed.
Outcomes Symptom score (frequency of cough, frequency of coughing bouts, symptoms associated
with cough, night-time cough)
BHR (methacholine challenge test).
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Pornsuriyasak 2005 (Continued)
Spirometry (FEV1, FVC, FEF 25%-75%).
Frequency of taking medications to relieve cough.
Number of medications to relieve cough.
Notes Main outcome: ICS ineffective in treating persistent post-URTI cough in previously
healthy individuals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, method not reported.
Allocation concealment (selection bias) Unclear risk Method not reported.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar attrition rates for treatment and
control groups.
Selective reporting (reporting bias) Unclear risk Number of participants screened and eli-
gible not reported, reasons for withdrawals
stated, all outcomes reported
Other bias Unclear risk Post-URTI cough not defined; parallel
group trial.
Ribeiro 2007
Methods Design: parallel group.
Randomisation: yes, random number table.
Blinding: double blind.
Withdrawals: none.
Participants Setting: Outpatient Respiratory Clinic of the Hospital São Paulo, general practitioners
and hospital clinics (Brazil)
Number screened: 147.
Number eligible: 64.
Number randomised: 64.
Number in treatment group: 44.
Number in control group: 20.
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Ribeiro 2007 (Continued)
Number of withdrawals (treatment:control): 0 (0:0).
Number completing trial (treatment:control): 64 (44:20).
Sex: 22 M, 42 F.
Age (years): mean 46.4 (SD 17.4) treatment, mean 50.1 (SD 18.1) control
Cough duration (weeks): mean 48.2 (SD 99.6) treatment, mean 36.7 (SD 45.5) control
Inclusion criteria: cough for at least 8 weeks with normal chest radiograph, plain sinus
radiographs in four positions, and ears, nose and throat examination
Exclusion criteria: previous gastroesophageal reflux disease diagnosis, positive 24-hour
oesophageal pH measurement, concurrent respiratory tract infections, and a history or
medical diagnosis of asthma, chronic obstructive pulmonary disease, or chronic rhinos-
inusitis (PND syndrome) and evidence of airflow limitation with a FEV1/FVC of ≤
70%, no use of medications for cough in the 4 weeks leading up to entry into the study
Baseline characteristics of treatment:control groups: PD20 (provocation dose causing a
decline in FEV1 of 20%) greater in treatment group (5.35 mg/mL ± 3.2 mg/mL versus
4.56 mg/mL ± 3.7 mg/mL; P value 0.01), otherwise comparable
Interventions ICS: chlorofluorocarbon-beclomethasone 250 µg, 2 puffs 3 times daily (1500 µg/day)
Control: placebo, 2 puffs 3 times daily.
Administration method: MDI.
Treatment duration: 2 weeks.
Co-interventions: none.
Outcomes Symptom diary: frequency (throughout the day), severity (on arising and throughout
the day), duration of coughing (on arising and throughout the day), sleep interruption
(throughout the night)
VAS.
Adverse events reported by participants.
Notes Main outcome: ICS provided an excellent response in a subgroup of participants with
chronic cough that did not correlate with atopy or airway hyper-responsiveness
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Simple randomisation in an unbalanced
design using a random number table at a
ratio of 2:1 (treatment versus control)
Allocation concealment (selection bias) Low risk Randomisation performed by an outside
observer.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, packaging of the study and
placebo was identical in appearance and
taste and identically marked
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind.
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Ribeiro 2007 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals.
Selective reporting (reporting bias) Unclear risk Adverse effects not reported as an outcome
of interest in methods section but is re-
ported in results, number screened and el-
igible reported, all outcomes reported
Other bias Low risk Parallel group trial.
Rytilä 2008
Methods Design: parallel group.
Randomisation: yes, computer-generated.
Blinding: double blind.
Withdrawals: stated.
Participants Setting: 23 study centres inFinland, Sweden,Norway,Greece,Hungary,UK andCanada;
participants were referred to specialists, who were the investigators in the study
Number screened: 229.
Number eligible: not reported.
Number randomised: 144.
Number in treatment group: 71.
Number in control group: 73.
Number of withdrawals (treatment:control): 23 (10:13).
Number completing trial (treatment:control): 121 (61:60).
Sex: 42 M, 99 F (of 141 with sex recorded).
Age: 20-67 years.
Cough duration: not reported, inclusion criteria ≥ 2 months.
Inclusion criteria: FEV1 ≥ 80% predicted; cough (with or without sputum production)
plus at least one additional symptom from chest tightness, wheezing, shortness of breath,
or exercise-induced cough or wheezing for ≥ 2 months but < 2 years; average symptom
score of ≥1 (scale 0-3) for cough and for sputum production during 7 days of the run-
in period (1-2 weeks)
Exclusion criteria: physician-diagnosed asthma;≥12% increase in absolute FEV1 during
reversibility testing at screening; average daily morning/evening peak expiratory flow
(PEF) variability ≥ 20% for the week prior to baseline; history of smoking within 12
months prior to screening or a smoking history > 10 pack-years; evidence of chronic
obstructive pulmonary disease, chronic cough due to PND, asthma, chronic bronchitis,
sinusitis or gastro-oesophageal reflux (carefulmedical history and radiographs of the chest
and paranasal sinuses were obtained); an URTI within 4 weeks prior to screening. People
with symptoms of allergic/nonallergic rhinitis were treated with nasal corticosteroids
and/or antihistamines before the study; such treatment could not be changed during the
study
Baseline characteristics of treatment:control groups: comparable
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Rytilä 2008 (Continued)
Interventions ICS: mometasone furoate 400 µg daily.
Control: placebo.
Administration method: DPI (Twisthaler).
Treatment duration: 8 weeks.
Co-interventions: salbutamol inhaler could be used as a reliever medication, no other
medications were allowed
Outcomes Symptom scores: cough, sputum production, wheeze, shortness of breath, chest tightness
and exercise-induced cough/wheeze
BHR (histamine or methacholine).
PEF.
Requirement for supplemental salbutamol use.
Sputum eosinophils, ECP.
Adverse events reported by patient.
Notes Main outcomes: ICS improved total morning symptom scores but not total evening
symptom scores. ICS improved all individual symptom scores, although this was not
always statistically significant. ICS improved morning and evening PEF and reduced
sputum eosinophils and ECP
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Randomisation code maintained in sealed
envelope
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double blind, identical-looking placebo
inhaler
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Similar withdrawal rates for treatment and
control groups; reasons for withdrawals re-
ported
Selective reporting (reporting bias) Unclear risk Some outcomes not reported (BHR at 8
weeks, individual symptom scores other
than wheeze and cough), PEF monitoring
not part of study design section but is re-
ported in methods, number eligible not re-
ported, number screened reported, reasons
for withdrawals stated
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Rytilä 2008 (Continued)
Other bias Low risk
Abbreviations
> = more than; < = less than; ≥ = greater than or equal to; BHR = bronchial hyper-responsiveness; CRP =
CXR = ; DPI = dry powder inhaler; ECP = eosinophilic cationic protein; F = female; FEF = forced expiratory flow; FEV1 = forced
expiratory volume in one second; FVC = forced vital capacity; GSK = GlaxoSmithKline; ICS = inhaled corticosteroids; M =male; MDI
= metered dose inhaler; N/A = not applicable; PC20 = ; PEF = peak; expiratory flow; PND = postnasal drip;URTI = upper respiratory
tract infection.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brightling 2000 Open label uncontrolled trial.
Cheriyan 1994 Retrospective uncontrolled trial.
Fujimoto 2003 Prospective uncontrolled trial of bronchodilator, antiallergic and inhaled or oral glucocorticoid therapy
Gillissen 2007 Inclusion criteria of post-infectious cough of between 3 and 14 days duration (i.e. acute cough)
Han 2009 Randomised trial of inhaled fluticasone versus oral codeine plus levodropropizine
Matsuoka 2010 Retrospective uncontrolled study.
Park 2007 Uncontrolled trial assessing roles of the capsaicin cough sensitivity test, methacholine bronchial provocation test
and induced sputum test in evaluation of chronic nonproductive cough
Rytilä 2000 Inclusion criteria of at least 2 of 6 respiratory symptoms (cough, chest tightness with wheezing, shortness of breath,
sputum production, wheezing or cough at exercise, and disturbed sleep), not necessarily always including cough
Stankovic 2010 Open-label, non-randomised trial of inhaled corticosteroid and β2 agonist versus oral β2 agonist.
Stankovik 2004 Open-label, non-randomised, uncontrolled trial of inhaled β2 agonist followed by ICS treatment.
Wei 2011 Prospective observational study of inhaled and oral bronchodilator therapy versus inhaled budesonide and oral
bronchodilator therapy for cough-variant asthma
Xu 2011 Comparison of 4, 8 and 16 weeks inhaled budesonide therapy for eosinophilic bronchitis; no placebo comparison
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Characteristics of studies awaiting assessment [ordered by study ID]
Tagaya 2009
Methods Design: parallel group.
Randomisation: yes, method not reported.
Blinding: not reported.
Withdrawals: not reported.
Participants Setting: not reported (Japan).
Number screened: not reported.
Number eligible: not reported.
Number randomised: 25.
Number in treatment group: not reported.
Number in control group: not reported.
Number of withdrawals (treatment:control): not reported.
Number completing trial (treatment:control): not reported.
Sex: not reported.
Age range: not reported.
Cough duration: not reported.
Inclusion criteria: CVA.
Exclusion criteria: not reported.
Baseline characteristics of treatment:control groups: not reported
Interventions ICS: salmeterol/fluticasone propionate combination 50/100 µg, once daily (100 µg/day)
Control: salmeterol 50 µg twice daily - different dose of salmeterol
Administration method: not reported.
Treatment duration: 12 weeks.
Co-interventions: long acting beta-adrenoreceptor agonist (LABA)
Outcomes Cough score.
FEV1.
PEF.
Sputum eosinophils, ECP.
Notes Main outcome: maintenance therapy with SFC improved cough symptoms, pulmonary function and airway inflam-
mation. Discontinuation caused worsening of the disease
Reported as abstract. Contacted Dr Tagaya but unpublished data not available. Awaiting publication of full paper
Tagaya 2011
Methods Design: parallel group.
Randomisation: yes, method not reported.
Blinding: not reported.
Withdrawals: not reported.
Participants Setting: multicentre trial (Japan).
Number screened: not reported.
Number eligible: not reported.
Number randomised: 27.
45Inhaled corticosteroids for subacute and chronic cough in adults (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tagaya 2011 (Continued)
Number in treatment group: 14.
Number in control group: 13.
Number of withdrawals (treatment:control): not reported.
Number completing trial (treatment:control): not reported.
Sex: not reported.
Age range: not reported.
Cough duration: not reported.
Inclusion criteria: CVA according to Japanese cough guidelines
Exclusion criteria: not reported.
Baseline characteristics of treatment:control groups: comparable
Interventions ICS: budesonide/formoterol combination 160/4.5 µg twice daily (total budesonide dose 320 µg/day)
Control: salmeterol 50 µg twice daily.
Administration method: DPI.
Treatment duration: 8 weeks.
Co-interventions: LABA, supplemental procaterol (SABA).
Outcomes Cough symptom score.
Cough and sputum assessment questionnaire (CASA-Q).
FEV1.
PEF.
Supplemental use of inhaled procaterol (SABA).
Sputum eosinophils, ECP.
Notes Main outcome: treatment decreased cough symptom scores, CASA-Q scores, diurnal variation of PEF, eosinophil
counts and ECP
Reported as abstract. Contacted Dr Tagaya but unpublished data not available. Awaiting publication of full paper
Abbreviations
CVA = cough-variant asthma; DPI = dry powder inhaler; ECP = eosinophilic cationic protein; FEV1 = forced expiratory volume in
one second; ICS = inhaled corticosteroids; PEF = peak expiratory flow; SFC = salmeterol/fluticasone propionate combination
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D A T A A N D A N A L Y S E S
Comparison 1. ICS versus Placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants with
clinical cure or significant
improvement (> 70% reduction
in cough severity measure) at
follow up (clinical success)
3 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Cough score 3 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 VAS 1 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Proportion of participants
with clinical cure or > 50%
reduction in cough severity
measure at follow up
4 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
3 Proportion of participants with
clinical cure at follow up
4 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
4 Mean change in cough score 5 346 Std. Mean Difference (IV, Fixed, 95% CI) -0.34 [-0.56, -0.13]
5 Mean change in cough measures
on VAS
2 Std. Mean Difference (Fixed, 95% CI) Totals not selected
6 Mean change in VAS after 2
weeks by final diagnosis [cm]
1 Mean Difference (Fixed, 95% CI) Totals not selected
6.1 PNDS 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 GORD 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 CVA 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
6.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Mean change in morning and
evening cough score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Morning cough score 4
weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Morning cough score 8
weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Evening cough score 4
weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Evening cough score 8
weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Mean change in morning and
evening total symptom score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Morning total symptom
score 4 weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Morning total symptom
score 8 weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Evening total symptom
score 4 weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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8.4 Evening total symptom
score 8 weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Mean change in cough frequency 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 After 1 week 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 After 2 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Mean change in cough severity 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 After 1 week 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 After 2 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Mean change in cough time of
day
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 After 1 week 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 After 2 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
12 Proportion without BHR after
treatment
1 94 Odds Ratio (M-H, Fixed, 95% CI) 1.28 [0.38, 4.34]
12.1 Baseline BHR 1 34 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [0.33, 4.93]
12.2 No baseline BHR 1 60 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [0.08, 22.15]
13 Mean change in BHR 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 Measured by
methacholine challenge
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 Measured by citric acid
challenge
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Change in FEV1 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 Non-smokers 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.2 Smokers 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Proportion requiring additional
medication
1 132 Odds Ratio (M-H, Fixed, 95% CI) 0.46 [0.23, 0.91]
15.1 Non-smokers 1 84 Odds Ratio (M-H, Fixed, 95% CI) 0.31 [0.13, 0.76]
15.2 Smokers 1 48 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.27, 2.63]
16 Mean change in sleep
interruption
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 After 1 week 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16.2 After 2 weeks 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Mean change in sputum ECP
[ng/mL]
1 Mean Difference (Fixed, 95% CI) -396.0 [-791.99, -0.
01]
18 Mean change in sputum ECP
by final diagnosis [ng/mL]
1 Mean Difference (Fixed, 95% CI) Totals not selected
18.1 PNDS 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
18.2 GORD 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
18.3 CVA 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
18.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
18.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Change in sputum total cells
[×106]
1 Mean Difference (Fixed, 95% CI) Subtotals only
19.1 PNDS 1 Mean Difference (Fixed, 95% CI) -1.5 [-11.95, 8.95]
19.2 GORD 1 Mean Difference (Fixed, 95% CI) -4.6 [-12.30, 3.10]
19.3 CVA 1 Mean Difference (Fixed, 95% CI) 3.4 [-7.05, 13.85]
19.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
19.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) -2.8 [-15.20, 9.60]
19.6 All causes 1 Mean Difference (Fixed, 95% CI) -1.0 [-8.55, 6.55]
20 Change in sputum neutrophils
[%]
1 Mean Difference (Fixed, 95% CI) Subtotals only
20.1 PNDS 1 Mean Difference (Fixed, 95% CI) -1.2 [-18.60, 16.20]
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20.2 GORD 1 Mean Difference (Fixed, 95% CI) -13.8 [-29.75, 2.15]
20.3 CVA 1 Mean Difference (Fixed, 95% CI) 0.9 [-19.90, 21.70]
20.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) 0.6 [-20.20, 21.40]
20.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) 5.3 [-14.20, 24.80]
20.6 All causes 1 Mean Difference (Fixed, 95% CI) 1.1 [-7.50, 9.70]
21 Change in sputum eosinophils
[%]
1 Mean Difference (Fixed, 95% CI) Subtotals only
21.1 PNDS 1 Mean Difference (Fixed, 95% CI) 0.0 [-2.05, 2.05]
21.2 GORD 1 Mean Difference (Fixed, 95% CI) -0.1 [0.00, 1.80]
21.3 CVA 1 Mean Difference (Fixed, 95% CI) -4.6 [-7.10, -2.10]
21.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) 1.5 [-0.95, 3.95]
21.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) 0.1 [-2.20, 2.40]
21.6 All causes 1 Mean Difference (Fixed, 95% CI) -0.7 [-1.75, 0.35]
22 Change in sputum lymphocytes
[%]
1 Mean Difference (Fixed, 95% CI) Subtotals only
22.1 PNDS 1 Mean Difference (Fixed, 95% CI) 0.0 [-0.35, 0.35]
22.2 GORD 1 Mean Difference (Fixed, 95% CI) 0.1 [-0.25, 0.45]
22.3 CVA 1 Mean Difference (Fixed, 95% CI) -0.3 [-0.70, 0.10]
22.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) -0.1 [-0.50, 0.30]
22.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) -0.1 [-0.50, 0.30]
22.6 All causes 1 Mean Difference (Fixed, 95% CI) -0.1 [-0.25, 0.05]
23 Change in sputum MPO
[µg/mL]
1 Mean Difference (Fixed, 95% CI) Subtotals only
23.1 PNDS 1 Mean Difference (Fixed, 95% CI) -34.0 [-113.30, 45.
30]
23.2 GORD 1 Mean Difference (Fixed, 95% CI) -17.7 [-97.05, 61.
65]
23.3 CVA 1 Mean Difference (Fixed, 95% CI) 70.0 [-98.30, 238.
30]
23.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) 133.5 [27.05, 239.
95]
23.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) 9.1 [-128.30, 146.
50]
23.6 All causes 1 Mean Difference (Fixed, 95% CI) 10.7 [-29.60, 51.00]
24 Change in sputum PGE2
[ng/mL]
1 Mean Difference (Fixed, 95% CI) -1.82 [-7.21, 3.56]
24.1 PNDS 1 Mean Difference (Fixed, 95% CI) 4.9 [-10.30, 20.10]
24.2 GORD 1 Mean Difference (Fixed, 95% CI) -4.7 [-20.85, 11.45]
24.3 CVA 1 Mean Difference (Fixed, 95% CI) 12.1 [-10.70, 34.90]
24.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) -11.6 [-30.25, 7.05]
24.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) -9.8 [-32.65, 13.05]
24.6 All causes 1 Mean Difference (Fixed, 95% CI) -1.9 [-9.05, 5.25]
25 Change in sputum LTB4
[ng/mL]
1 Mean Difference (Fixed, 95% CI) Subtotals only
25.1 PNDS 1 Mean Difference (Fixed, 95% CI) 5.1 [-32.85, 43.05]
25.2 GORD 1 Mean Difference (Fixed, 95% CI) 1.70 [-36.30, 39.70]
25.3 CVA 1 Mean Difference (Fixed, 95% CI) 25.6 [-18.25, 69.45]
25.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) -15.7 [-49.65, 18.
25]
25.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) -9.2 [-53.05, 34.65]
25.6 All causes 1 Mean Difference (Fixed, 95% CI) 2.3 [-13.20, 17.80]
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26 Change in sputum Cys-LT
[ng/mL]
1 Mean Difference (Fixed, 95% CI) Subtotals only
26.1 PNDS 1 Mean Difference (Fixed, 95% CI) 0.1 [-1.50, 1.70]
26.2 GORD 1 Mean Difference (Fixed, 95% CI) -0.2 [-1.85, 1.45]
26.3 CVA 1 Mean Difference (Fixed, 95% CI) -0.6 [-2.85, 1.65]
26.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) -1.4 [-3.25, 0.45]
26.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) 0.3 [-2.30, 2.90]
26.6 All causes 1 Mean Difference (Fixed, 95% CI) -0.4 [-1.20, 0.40]
27 Change in sputum IL-8
[ng/mL]
1 Mean Difference (Fixed, 95% CI) Subtotals only
27.1 PNDS 1 Mean Difference (Fixed, 95% CI) -3.5 [-61.95, 54.95]
27.2 GORD 1 Mean Difference (Fixed, 95% CI) -27.0 [-88.95, 34.
95]
27.3 CVA 1 Mean Difference (Fixed, 95% CI) 1.5 [-86.10, 89.10]
27.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) -74.7 [-146.30, -3.
10]
27.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) -20.9 [-122.10, 80.
30]
27.6 All causes 1 Mean Difference (Fixed, 95% CI) -21.5 [-48.25, 5.25]
28 Change in sputum TNF-α
[ng/mL]
1 Mean Difference (Fixed, 95% CI) Subtotals only
28.1 PNDS 1 Mean Difference (Fixed, 95% CI) -3.9 [-17.70, 9.90]
28.2 GORD 1 Mean Difference (Fixed, 95% CI) 3.6 [-8.40, 15.60]
28.3 CVA 1 Mean Difference (Fixed, 95% CI) 0.0 [-13.80, 13.80]
28.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) 0.4 [-10.30, 11.10]
28.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
28.6 All causes 1 Mean Difference (Fixed, 95% CI) 0.3 [-4.85, 5.45]
29 Change in eNO [ppb] 1 Mean Difference (Fixed, 95% CI) Subtotals only
29.1 PNDS 1 Mean Difference (Fixed, 95% CI) 0.0 [0.00, 2.00]
29.2 GORD 1 Mean Difference (Fixed, 95% CI) -3.1 [-5.75, -0.45]
29.3 CVA 1 Mean Difference (Fixed, 95% CI) -3.3 [-6.45, -0.15]
29.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) -0.90 [-4.50, 2.70]
29.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) -1.4 [-4.85, 2.05]
29.6 All causes 1 Mean Difference (Fixed, 95% CI) -2.1 [-3.56, -0.64]
30 Change in exhaled CO [ppm] 1 Mean Difference (Fixed, 95% CI) Subtotals only
30.1 PNDS 1 Mean Difference (Fixed, 95% CI) -0.1 [-0.60, 0.40]
30.2 GORD 1 Mean Difference (Fixed, 95% CI) -0.3 [1.00, 0.40]
30.3 CVA 1 Mean Difference (Fixed, 95% CI) -0.3 [-1.10, 0.50]
30.4 Bronchiectasis 1 Mean Difference (Fixed, 95% CI) -0.7 [-1.60, 0.20]
30.5 Idiopathic cough 1 Mean Difference (Fixed, 95% CI) -0.1 [-0.95, 0.75]
30.6 All causes 1 Mean Difference (Fixed, 95% CI) -0.34 [-0.66, -0.02]
31 Proportion with adverse effects 4 381 Odds Ratio (M-H, Fixed, 95% CI) 1.67 [0.92, 3.04]
32 Proportion with specific adverse
effects
2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
32.1 Hoarseness 2 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
32.2 Sore throat 2 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
32.3 Oral candidiasis 2 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
33 Proportion with severe adverse
effects
3 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 ICS versus Placebo, Outcome 1 Proportion of participants with clinical cure or
significant improvement (> 70% reduction in cough severity measure) at follow up (clinical success).
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 1 Proportion of participants with clinical cure or significant improvement (> 70% reduction in cough severity measure) at follow up (clinical success)
Study or subgroup Favours Placebo Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cough score
Boulet 1994 2/7 2/7 1.00 [ 0.10, 10.17 ]
Ponsioen 2005 (1) 26/52 23/50 1.17 [ 0.54, 2.55 ]
Ribeiro 2007 34/44 2/20 30.60 [ 6.04, 154.95 ]
2 VAS
Ribeiro 2007 36/44 3/20 25.50 [ 6.00, 108.37 ]
0.001 0.01 0.1 1 10 100 1000
Favours Placebo Favours ICS
(1) Acute cough patients excluded
Analysis 1.2. Comparison 1 ICS versus Placebo, Outcome 2 Proportion of participants with clinical cure or
> 50% reduction in cough severity measure at follow up.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 2 Proportion of participants with clinical cure or > 50% reduction in cough severity measure at follow up
Study or subgroup ICS Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boulet 1994 (1) 2/7 3/7 0.53 [ 0.06, 4.91 ]
Pizzichini 1999 (2) 4/25 0/25 10.67 [ 0.54, 209.64 ]
Ponsioen 2005 (3) 35/52 31/50 1.26 [ 0.56, 2.85 ]
Ribeiro 2007 (4) 36/44 3/20 25.50 [ 6.00, 108.37 ]
0.001 0.01 0.1 1 10 100 1000
Favours Placebo Favours ICS
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(1) Cough symptom score [0-10]
(2) VAS score
(3) Cough score [0-3]; acute cough patients excluded
(4) VAS score
Analysis 1.3. Comparison 1 ICS versus Placebo, Outcome 3 Proportion of participants with clinical cure at
follow up.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 3 Proportion of participants with clinical cure at follow up
Study or subgroup ICS Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boulet 1994 1/7 0/7 3.46 [ 0.12, 100.51 ]
Ponsioen 2005 (1) 23/52 13/50 2.26 [ 0.98, 5.21 ]
Ribeiro 2007 38/44 3/20 35.89 [ 8.01, 160.72 ]
Rytila¨ 2008 (2) 20/70 18/70 1.16 [ 0.55, 2.44 ]
0.005 0.1 1 10 200
Favours Placebo Favours ICS
(1) Acute cough patients excluded; defined by cough score of 0
(2) Defined by a symptom score of 0-2 out of 36
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Analysis 1.4. Comparison 1 ICS versus Placebo, Outcome 4 Mean change in cough score.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 4 Mean change in cough score
Study or subgroup ICS Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Boulet 1994 7 -1.15 (1.56) 7 -0.24 (0.88) 3.9 % -0.67 [ -1.76, 0.42 ]
Ponsioen 2005 (1) 52 -2.3846 (1.76484) 50 -2 (1.66599) 30.7 % -0.22 [ -0.61, 0.17 ]
Pornsuriyasak 2005 14 -1.36 (1.74) 12 -1 (1.28) 7.8 % -0.23 [ -1.00, 0.55 ]
Ribeiro 2007 44 -1.37 (1.21) 20 -0.54 (0.7) 15.6 % -0.76 [ -1.31, -0.21 ]
Rytila¨ 2008 (2) 70 -0.44 (0.669328) 70 -0.26 (0.66933) 42.0 % -0.27 [ -0.60, 0.07 ]
Total (95% CI) 187 159 100.0 % -0.34 [ -0.56, -0.13 ]
Heterogeneity: Chi2 = 3.25, df = 4 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 3.12 (P = 0.0018)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours ICS Favours Placebo
(1) Acute cough patients excluded
(2) Morning cough score
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Analysis 1.5. Comparison 1 ICS versus Placebo, Outcome 5 Mean change in cough measures on VAS.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 5 Mean change in cough measures on VAS
Study or subgroup
Std. Mean
Difference
(SE)
Std.
Mean
Difference
Std.
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Chaudhuri 2004 (1) -22.3 (13.1888) -22.30 [ -48.15, 3.55 ]
Ribeiro 2007 (2) -63.9 (8.2384) -63.90 [ -80.05, -47.75 ]
-100 -50 0 50 100
Favours ICS Favours Placebo
(1) cm
(2) %
54Inhaled corticosteroids for subacute and chronic cough in adults (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 ICS versus Placebo, Outcome 6 Mean change in VAS after 2 weeks by final
diagnosis [cm].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 6 Mean change in VAS after 2 weeks by final diagnosis [cm]
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 0.9 (0.459184) 0.90 [ 0.00, 1.80 ]
2 GORD
Chaudhuri 2004 1.2 (0.586735) 1.20 [ 0.05, 2.35 ]
3 CVA
Chaudhuri 2004 1.4 (0.688776) 1.40 [ 0.05, 2.75 ]
4 Bronchiectasis
Chaudhuri 2004 0.7 (0.841837) 0.70 [ -0.95, 2.35 ]
5 Idiopathic cough
Chaudhuri 2004 0.5 (0.790816) 0.50 [ -1.05, 2.05 ]
-2 -1 0 1 2
Favours ICS Favours Placebo
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Analysis 1.7. Comparison 1 ICS versus Placebo, Outcome 7 Mean change in morning and evening cough
score.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 7 Mean change in morning and evening cough score
Study or subgroup ICS Placebo
Mean
Difference
Mean
Difference
N
Mean(SD)[scale
0-6] N
Mean(SD)[scale
0-6] IV,Fixed,95% CI IV,Fixed,95% CI
1 Morning cough score 4 weeks
Rytila¨ 2008 70 -0.44 (0.669328) 70 -0.26 (0.66933) -0.18 [ -0.40, 0.04 ]
2 Morning cough score 8 weeks
Rytila¨ 2008 70 -0.58 (0.752994) 70 -0.53 (0.83666) -0.05 [ -0.31, 0.21 ]
3 Evening cough score 4 weeks
Rytila¨ 2008 70 -0.48 (0.585662) 70 -0.32 (0.58566) -0.16 [ -0.35, 0.03 ]
4 Evening cough score 8 weeks
Rytila¨ 2008 70 -0.58 (0.752994) 70 -0.56 (0.83666) -0.02 [ -0.28, 0.24 ]
-1 -0.5 0 0.5 1
Favours ICS Favours Placebo
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Analysis 1.8. Comparison 1 ICS versus Placebo, Outcome 8 Mean change in morning and evening total
symptom score.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 8 Mean change in morning and evening total symptom score
Study or subgroup ICS Placebo
Mean
Difference
Mean
Difference
N
Mean(SD)[scale
0-6] N
Mean(SD)[scale
0-6] IV,Fixed,95% CI IV,Fixed,95% CI
1 Morning total symptom score 4 weeks
Rytila¨ 2008 70 -1.53 (2.2589821) 70 -0.8 (2.34265) -0.73 [ -1.49, 0.03 ]
2 Morning total symptom score 8 weeks
Rytila¨ 2008 70 -2.16 (2.2589821) 70 -1.35 (2.34265) -0.81 [ -1.57, -0.05 ]
3 Evening total symptom score 4 weeks
Rytila¨ 2008 70 -1.69 (2.2589821) 70 -1.1 (2.25898) -0.59 [ -1.34, 0.16 ]
4 Evening total symptom score 8 weeks
Rytila¨ 2008 70 -2.25 (2.5936461) 70 -1.65 (2.67731) -0.60 [ -1.47, 0.27 ]
-2 -1 0 1 2
Favours ICS Favours Placebo
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Analysis 1.9. Comparison 1 ICS versus Placebo, Outcome 9 Mean change in cough frequency.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 9 Mean change in cough frequency
Study or subgroup ICS Placebo
Mean
Difference
Mean
Difference
N
Mean(SD)[scale
0-4] N
Mean(SD)[scale
0-4] IV,Fixed,95% CI IV,Fixed,95% CI
1 After 1 week
Ribeiro 2007 44 -0.81 (0.64) 20 -0.44 (0.72) -0.37 [ -0.74, 0.00 ]
2 After 2 weeks
Ribeiro 2007 44 -1.82 (1.11) 20 -0.67 (0.67) -1.15 [ -1.59, -0.71 ]
-1 -0.5 0 0.5 1
Favours ICS Favours Placebo
Analysis 1.10. Comparison 1 ICS versus Placebo, Outcome 10 Mean change in cough severity.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 10 Mean change in cough severity
Study or subgroup ICS Placebo
Mean
Difference
Mean
Difference
N
Mean(SD)[scale
0-4] N
Mean(SD)[scale
0-4] IV,Fixed,95% CI IV,Fixed,95% CI
1 After 1 week
Ribeiro 2007 44 -0.54 (0.33) 20 -0.37 (0.45) -0.17 [ -0.39, 0.05 ]
2 After 2 weeks
Ribeiro 2007 44 -1.21 (0.92) 20 -0.6 (0.6) -0.61 [ -0.99, -0.23 ]
-1 -0.5 0 0.5 1
Favours ICS Favours Placebo
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Analysis 1.11. Comparison 1 ICS versus Placebo, Outcome 11 Mean change in cough time of day.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 11 Mean change in cough time of day
Study or subgroup ICS Placebo
Mean
Difference
Mean
Difference
N
Mean(SD)[scale
0-4] N
Mean(SD)[scale
0-4] IV,Fixed,95% CI IV,Fixed,95% CI
1 After 1 week
Ribeiro 2007 44 -0.73 (0.7) 20 -0.29 (0.39) -0.44 [ -0.71, -0.17 ]
2 After 2 weeks
Ribeiro 2007 44 -1.8 (1.21) 20 -0.55 (0.88) -1.25 [ -1.78, -0.72 ]
-2 -1 0 1 2
Favours ICS Favours Placebo
Analysis 1.12. Comparison 1 ICS versus Placebo, Outcome 12 Proportion without BHR after treatment.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 12 Proportion without BHR after treatment
Study or subgroup ICS Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline BHR
Ponsioen 2005 8/15 9/19 81.6 % 1.27 [ 0.33, 4.93 ]
Subtotal (95% CI) 15 19 81.6 % 1.27 [ 0.33, 4.93 ]
Total events: 8 (ICS), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
2 No baseline BHR
Ponsioen 2005 33/34 25/26 18.4 % 1.32 [ 0.08, 22.15 ]
Subtotal (95% CI) 34 26 18.4 % 1.32 [ 0.08, 22.15 ]
0.01 0.1 1 10 100
Favours Placebo Favours ICS
(Continued . . . )
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(. . . Continued)
Study or subgroup ICS Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 33 (ICS), 25 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.19 (P = 0.85)
Total (95% CI) 49 45 100.0 % 1.28 [ 0.38, 4.34 ]
Total events: 41 (ICS), 34 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
0.01 0.1 1 10 100
Favours Placebo Favours ICS
Analysis 1.13. Comparison 1 ICS versus Placebo, Outcome 13 Mean change in BHR.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 13 Mean change in BHR
Study or subgroup ICS Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[mg/mL] N Mean(SD)[mg/mL] IV,Fixed,95% CI IV,Fixed,95% CI
1 Measured by methacholine challenge
Boulet 1994 (1) 7 8.56 (23.42) 6 9.55 (45.09) -0.99 [ -41.02, 39.04 ]
2 Measured by citric acid challenge
Boulet 1994 6 103.33 (115.94) 5 64 (50.6) 39.33 [ -63.50, 142.16 ]
-1000 -500 0 500 1000
Favours Placebo Favours ICS
(1) No (PC20)
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Analysis 1.14. Comparison 1 ICS versus Placebo, Outcome 14 Change in FEV1.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 14 Change in FEV1
Study or subgroup ICS Placebo
Mean
Difference
Mean
Difference
N Mean(SD)[L/s] N Mean(SD)[L/s] IV,Fixed,95% CI IV,Fixed,95% CI
1 Non-smokers
Ponsioen 2005 33 0.0636 (0.30568) 32 -0.04 (0.17278) 0.11 [ -0.01, 0.23 ]
2 Smokers
Ponsioen 2005 19 0.0916 (0.15174) 17 0.02 (0.26284) 0.07 [ -0.07, 0.21 ]
-0.2 -0.1 0 0.1 0.2
Favours ICS Favours Placebo
Analysis 1.15. Comparison 1 ICS versus Placebo, Outcome 15 Proportion requiring additional medication.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 15 Proportion requiring additional medication
Study or subgroup ICS Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Non-smokers
Ponsioen 2005 (1) 16/41 29/43 72.6 % 0.31 [ 0.13, 0.76 ]
Subtotal (95% CI) 41 43 72.6 % 0.31 [ 0.13, 0.76 ]
Total events: 16 (ICS), 29 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.57 (P = 0.010)
2 Smokers
Ponsioen 2005 (2) 12/24 13/24 27.4 % 0.85 [ 0.27, 2.63 ]
Subtotal (95% CI) 24 24 27.4 % 0.85 [ 0.27, 2.63 ]
Total events: 12 (ICS), 13 (Placebo)
0.001 0.01 0.1 1 10 100 1000
Favours ICS Favours Placebo
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(. . . Continued)
Study or subgroup ICS Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 65 67 100.0 % 0.46 [ 0.23, 0.91 ]
Total events: 28 (ICS), 42 (Placebo)
Heterogeneity: Chi2 = 1.87, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 2.22 (P = 0.026)
Test for subgroup differences: Chi2 = 1.87, df = 1 (P = 0.17), I2 =47%
0.001 0.01 0.1 1 10 100 1000
Favours ICS Favours Placebo
(1) Requirement for additional medication after the treatment period
(2) Requirement for additional medication after the treatment period
Analysis 1.16. Comparison 1 ICS versus Placebo, Outcome 16 Mean change in sleep interruption.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 16 Mean change in sleep interruption
Study or subgroup ICS Placebo
Mean
Difference
Mean
Difference
N
Mean(SD)[scale
0-4] N
Mean(SD)[scale
0-4] IV,Fixed,95% CI IV,Fixed,95% CI
1 After 1 week
Ribeiro 2007 44 -0.32 (0.9) 20 -0.19 (0.23) -0.13 [ -0.41, 0.15 ]
2 After 2 weeks
Ribeiro 2007 44 -0.64 (1.23) 20 -0.35 (0.59) -0.29 [ -0.74, 0.16 ]
-1 -0.5 0 0.5 1
Favours ICS Favours Placebo
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Analysis 1.17. Comparison 1 ICS versus Placebo, Outcome 17 Mean change in sputum ECP [ng/mL].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 17 Mean change in sputum ECP [ng/mL]
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Chaudhuri 2004 -396 (202.0408) 100.0 % -396.00 [ -791.99, -0.01 ]
Total (95% CI) 100.0 % -396.00 [ -791.99, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
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Analysis 1.18. Comparison 1 ICS versus Placebo, Outcome 18 Mean change in sputum ECP by final
diagnosis [ng/mL].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 18 Mean change in sputum ECP by final diagnosis [ng/mL]
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 -506 (333.6735) -506.00 [ -1159.99, 147.99 ]
2 GORD
Chaudhuri 2004 62 (314.5408) 62.00 [ -554.49, 678.49 ]
3 CVA
Chaudhuri 2004 80 (666.8367) 80.00 [ -1226.98, 1386.98 ]
4 Bronchiectasis
Chaudhuri 2004 -142 (421.6837) -142.00 [ -968.48, 684.48 ]
5 Idiopathic cough
Chaudhuri 2004 -248 (544.898) -248.00 [ -1315.98, 819.98 ]
-1000 -500 0 500 1000
Favours ICS Favours Placebo
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Analysis 1.19. Comparison 1 ICS versus Placebo, Outcome 19 Change in sputum total cells [×106].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 19 Change in sputum total cells [ 10
6
]
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 -1.5 (5.331633) -1.50 [ -11.95, 8.95 ]
Subtotal (95% CI) -1.50 [ -11.95, 8.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
2 GORD
Chaudhuri 2004 -4.6 (3.928571) -4.60 [ -12.30, 3.10 ]
Subtotal (95% CI) -4.60 [ -12.30, 3.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
3 CVA
Chaudhuri 2004 3.4 (5.331633) 3.40 [ -7.05, 13.85 ]
Subtotal (95% CI) 3.40 [ -7.05, 13.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
4 Bronchiectasis
Chaudhuri 2004 0 (0) 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
5 Idiopathic cough
Chaudhuri 2004 -2.8 (6.326531) -2.80 [ -15.20, 9.60 ]
Subtotal (95% CI) -2.80 [ -15.20, 9.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
6 All causes
Chaudhuri 2004 -1 (3.852041) -1.00 [ -8.55, 6.55 ]
Subtotal (95% CI) -1.00 [ -8.55, 6.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
Test for subgroup differences: Chi2 = 1.52, df = 4 (P = 0.82), I2 =0.0%
-50 -25 0 25 50
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Analysis 1.20. Comparison 1 ICS versus Placebo, Outcome 20 Change in sputum neutrophils [%].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 20 Change in sputum neutrophils [%]
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 -1.2 (8.877551) 100.0 % -1.20 [ -18.60, 16.20 ]
Subtotal (95% CI) 100.0 % -1.20 [ -18.60, 16.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
2 GORD
Chaudhuri 2004 -13.8 (8.137755) 100.0 % -13.80 [ -29.75, 2.15 ]
Subtotal (95% CI) 100.0 % -13.80 [ -29.75, 2.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
3 CVA
Chaudhuri 2004 0.9 (10.61224) 100.0 % 0.90 [ -19.90, 21.70 ]
Subtotal (95% CI) 100.0 % 0.90 [ -19.90, 21.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
4 Bronchiectasis
Chaudhuri 2004 0.6 (10.61224) 100.0 % 0.60 [ -20.20, 21.40 ]
Subtotal (95% CI) 100.0 % 0.60 [ -20.20, 21.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
5 Idiopathic cough
Chaudhuri 2004 5.3 (9.94898) 100.0 % 5.30 [ -14.20, 24.80 ]
Subtotal (95% CI) 100.0 % 5.30 [ -14.20, 24.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
6 All causes
Chaudhuri 2004 1.1 (4.387755) 100.0 % 1.10 [ -7.50, 9.70 ]
Subtotal (95% CI) 100.0 % 1.10 [ -7.50, 9.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 3.16, df = 5 (P = 0.68), I2 =0.0%
-100 -50 0 50 100
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Analysis 1.21. Comparison 1 ICS versus Placebo, Outcome 21 Change in sputum eosinophils [%].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 21 Change in sputum eosinophils [%]
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 0 (1.045918) 100.0 % 0.0 [ -2.05, 2.05 ]
Subtotal (95% CI) 100.0 % 0.0 [ -2.05, 2.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 GORD
Chaudhuri 2004 -0.1 (0.969388) 100.0 % -0.10 [ -2.00, 1.80 ]
Subtotal (95% CI) 100.0 % -0.10 [ -2.00, 1.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
3 CVA
Chaudhuri 2004 -4.6 (1.27551) 100.0 % -4.60 [ -7.10, -2.10 ]
Subtotal (95% CI) 100.0 % -4.60 [ -7.10, -2.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.61 (P = 0.00031)
4 Bronchiectasis
Chaudhuri 2004 1.5 (1.25) 100.0 % 1.50 [ -0.95, 3.95 ]
Subtotal (95% CI) 100.0 % 1.50 [ -0.95, 3.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
5 Idiopathic cough
Chaudhuri 2004 0.1 (1.173469) 100.0 % 0.10 [ -2.20, 2.40 ]
Subtotal (95% CI) 100.0 % 0.10 [ -2.20, 2.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
6 All causes
Chaudhuri 2004 -0.7 (0.5357) 100.0 % -0.70 [ -1.75, 0.35 ]
Subtotal (95% CI) 100.0 % -0.70 [ -1.75, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 13.64, df = 5 (P = 0.02), I2 =63%
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Analysis 1.22. Comparison 1 ICS versus Placebo, Outcome 22 Change in sputum lymphocytes [%].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 22 Change in sputum lymphocytes [%]
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 0 (0.178571) 100.0 % 0.0 [ -0.35, 0.35 ]
Subtotal (95% CI) 100.0 % 0.0 [ -0.35, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 GORD
Chaudhuri 2004 0.1 (0.178571) 100.0 % 0.10 [ -0.25, 0.45 ]
Subtotal (95% CI) 100.0 % 0.10 [ -0.25, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
3 CVA
Chaudhuri 2004 -0.3 (0.204082) 100.0 % -0.30 [ -0.70, 0.10 ]
Subtotal (95% CI) 100.0 % -0.30 [ -0.70, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
4 Bronchiectasis
Chaudhuri 2004 -0.1 (0.204082) 100.0 % -0.10 [ -0.50, 0.30 ]
Subtotal (95% CI) 100.0 % -0.10 [ -0.50, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
5 Idiopathic cough
Chaudhuri 2004 -0.1 (0.204082) 100.0 % -0.10 [ -0.50, 0.30 ]
Subtotal (95% CI) 100.0 % -0.10 [ -0.50, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
6 All causes
Chaudhuri 2004 -0.1 (0.076531) 100.0 % -0.10 [ -0.25, 0.05 ]
Subtotal (95% CI) 100.0 % -0.10 [ -0.25, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 2.46, df = 5 (P = 0.78), I2 =0.0%
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Analysis 1.23. Comparison 1 ICS versus Placebo, Outcome 23 Change in sputum MPO [µg/mL].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 23 Change in sputum MPO [ g/mL]
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 -34 (40.45918) 100.0 % -34.00 [ -113.30, 45.30 ]
Subtotal (95% CI) 100.0 % -34.00 [ -113.30, 45.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
2 GORD
Chaudhuri 2004 -17.7 (40.48469) 100.0 % -17.70 [ -97.05, 61.65 ]
Subtotal (95% CI) 100.0 % -17.70 [ -97.05, 61.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
3 CVA
Chaudhuri 2004 70 (85.86735) 100.0 % 70.00 [ -98.30, 238.30 ]
Subtotal (95% CI) 100.0 % 70.00 [ -98.30, 238.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
4 Bronchiectasis
Chaudhuri 2004 133.5 (54.31122) 100.0 % 133.50 [ 27.05, 239.95 ]
Subtotal (95% CI) 100.0 % 133.50 [ 27.05, 239.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
5 Idiopathic cough
Chaudhuri 2004 9.1 (70.10204) 100.0 % 9.10 [ -128.30, 146.50 ]
Subtotal (95% CI) 100.0 % 9.10 [ -128.30, 146.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
6 All causes
Chaudhuri 2004 10.7 (20.56122) 100.0 % 10.70 [ -29.60, 51.00 ]
Subtotal (95% CI) 100.0 % 10.70 [ -29.60, 51.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 7.30, df = 5 (P = 0.20), I2 =31%
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Analysis 1.24. Comparison 1 ICS versus Placebo, Outcome 24 Change in sputum PGE2 [ng/mL].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 24 Change in sputum PGE2 [ng/mL]
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 4.9 (7.755102) 12.6 % 4.90 [ -10.30, 20.10 ]
Subtotal (95% CI) 12.6 % 4.90 [ -10.30, 20.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 GORD
Chaudhuri 2004 -4.7 (8.239796) 11.1 % -4.70 [ -20.85, 11.45 ]
Subtotal (95% CI) 11.1 % -4.70 [ -20.85, 11.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
3 CVA
Chaudhuri 2004 12.1 (11.63265) 5.6 % 12.10 [ -10.70, 34.90 ]
Subtotal (95% CI) 5.6 % 12.10 [ -10.70, 34.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
4 Bronchiectasis
Chaudhuri 2004 -11.6 (9.515306) 8.3 % -11.60 [ -30.25, 7.05 ]
Subtotal (95% CI) 8.3 % -11.60 [ -30.25, 7.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
5 Idiopathic cough
Chaudhuri 2004 -9.8 (11.65816) 5.6 % -9.80 [ -32.65, 13.05 ]
Subtotal (95% CI) 5.6 % -9.80 [ -32.65, 13.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
6 All causes
Chaudhuri 2004 -1.9 (3.647959) 56.8 % -1.90 [ -9.05, 5.25 ]
Subtotal (95% CI) 56.8 % -1.90 [ -9.05, 5.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Total (95% CI) 100.0 % -1.82 [ -7.21, 3.56 ]
Heterogeneity: Chi2 = 3.83, df = 5 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Chi2 = 3.83, df = 5 (P = 0.57), I2 =0.0%
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Analysis 1.25. Comparison 1 ICS versus Placebo, Outcome 25 Change in sputum LTB4 [ng/mL].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 25 Change in sputum LTB4 [ng/mL]
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 5.1 (19.36224) 100.0 % 5.10 [ -32.85, 43.05 ]
Subtotal (95% CI) 100.0 % 5.10 [ -32.85, 43.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
2 GORD
Chaudhuri 2004 1.7 (19.38776) 100.0 % 1.70 [ -36.30, 39.70 ]
Subtotal (95% CI) 100.0 % 1.70 [ -36.30, 39.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
3 CVA
Chaudhuri 2004 25.6 (22.37245) 100.0 % 25.60 [ -18.25, 69.45 ]
Subtotal (95% CI) 100.0 % 25.60 [ -18.25, 69.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
4 Bronchiectasis
Chaudhuri 2004 -15.7 (17.32143) 100.0 % -15.70 [ -49.65, 18.25 ]
Subtotal (95% CI) 100.0 % -15.70 [ -49.65, 18.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
5 Idiopathic cough
Chaudhuri 2004 -9.2 (22.37245) 100.0 % -9.20 [ -53.05, 34.65 ]
Subtotal (95% CI) 100.0 % -9.20 [ -53.05, 34.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
6 All causes
Chaudhuri 2004 2.3 (7.908163) 100.0 % 2.30 [ -13.20, 17.80 ]
Subtotal (95% CI) 100.0 % 2.30 [ -13.20, 17.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 2.42, df = 5 (P = 0.79), I2 =0.0%
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Analysis 1.26. Comparison 1 ICS versus Placebo, Outcome 26 Change in sputum Cys-LT [ng/mL].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 26 Change in sputum Cys-LT [ng/mL]
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 0.1 (0.816327) 100.0 % 0.10 [ -1.50, 1.70 ]
Subtotal (95% CI) 100.0 % 0.10 [ -1.50, 1.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
2 GORD
Chaudhuri 2004 -0.2 (0.841837) 100.0 % -0.20 [ -1.85, 1.45 ]
Subtotal (95% CI) 100.0 % -0.20 [ -1.85, 1.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
3 CVA
Chaudhuri 2004 -0.6 (1.147959) 100.0 % -0.60 [ -2.85, 1.65 ]
Subtotal (95% CI) 100.0 % -0.60 [ -2.85, 1.65 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
4 Bronchiectasis
Chaudhuri 2004 -1.4 (0.943878) 100.0 % -1.40 [ -3.25, 0.45 ]
Subtotal (95% CI) 100.0 % -1.40 [ -3.25, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
5 Idiopathic cough
Chaudhuri 2004 0.3 (1.326531) 100.0 % 0.30 [ -2.30, 2.90 ]
Subtotal (95% CI) 100.0 % 0.30 [ -2.30, 2.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
6 All causes
Chaudhuri 2004 -0.4 (0.408163) 100.0 % -0.40 [ -1.20, 0.40 ]
-2 -1 0 1 2
Favours ICS Favours Placebo
(Continued . . . )
72Inhaled corticosteroids for subacute and chronic cough in adults (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 100.0 % -0.40 [ -1.20, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Chi2 = 1.86, df = 5 (P = 0.87), I2 =0.0%
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Analysis 1.27. Comparison 1 ICS versus Placebo, Outcome 27 Change in sputum IL-8 [ng/mL].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 27 Change in sputum IL-8 [ng/mL]
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 -3.5 (29.82143) 100.0 % -3.50 [ -61.95, 54.95 ]
Subtotal (95% CI) 100.0 % -3.50 [ -61.95, 54.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
2 GORD
Chaudhuri 2004 -27 (31.60714) 100.0 % -27.00 [ -88.95, 34.95 ]
Subtotal (95% CI) 100.0 % -27.00 [ -88.95, 34.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
3 CVA
Chaudhuri 2004 1.5 (44.69388) 100.0 % 1.50 [ -86.10, 89.10 ]
Subtotal (95% CI) 100.0 % 1.50 [ -86.10, 89.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
4 Bronchiectasis
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(. . . Continued)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Chaudhuri 2004 -74.7 (36.53061) 100.0 % -74.70 [ -146.30, -3.10 ]
Subtotal (95% CI) 100.0 % -74.70 [ -146.30, -3.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.04 (P = 0.041)
5 Idiopathic cough
Chaudhuri 2004 -20.9 (51.63265) 100.0 % -20.90 [ -122.10, 80.30 ]
Subtotal (95% CI) 100.0 % -20.90 [ -122.10, 80.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
6 All causes
Chaudhuri 2004 -21.5 (13.64796) 100.0 % -21.50 [ -48.25, 5.25 ]
Subtotal (95% CI) 100.0 % -21.50 [ -48.25, 5.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.12)
Test for subgroup differences: Chi2 = 2.76, df = 5 (P = 0.74), I2 =0.0%
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Analysis 1.28. Comparison 1 ICS versus Placebo, Outcome 28 Change in sputum TNF-α [ng/mL].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 28 Change in sputum TNF- [ng/mL]
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 -3.9 (7.040816) -3.90 [ -17.70, 9.90 ]
Subtotal (95% CI) -3.90 [ -17.70, 9.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 GORD
Chaudhuri 2004 3.6 (6.122449) 3.60 [ -8.40, 15.60 ]
Subtotal (95% CI) 3.60 [ -8.40, 15.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
3 CVA
Chaudhuri 2004 0 (7.040816) 0.0 [ -13.80, 13.80 ]
Subtotal (95% CI) 0.0 [ -13.80, 13.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Bronchiectasis
Chaudhuri 2004 0.4 (5.459184) 0.40 [ -10.30, 11.10 ]
Subtotal (95% CI) 0.40 [ -10.30, 11.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
5 Idiopathic cough
Chaudhuri 2004 (1) 0 (0) 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
6 All causes
Chaudhuri 2004 0.3 (2.627551) 0.30 [ -4.85, 5.45 ]
Subtotal (95% CI) 0.30 [ -4.85, 5.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 0.65, df = 4 (P = 0.96), I2 =0.0%
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Analysis 1.29. Comparison 1 ICS versus Placebo, Outcome 29 Change in eNO [ppb].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 29 Change in eNO [ppb]
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 0 (1.020408) 100.0 % 0.0 [ -2.00, 2.00 ]
Subtotal (95% CI) 100.0 % 0.0 [ -2.00, 2.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 GORD
Chaudhuri 2004 -3.1 (1.352041) 100.0 % -3.10 [ -5.75, -0.45 ]
Subtotal (95% CI) 100.0 % -3.10 [ -5.75, -0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
3 CVA
Chaudhuri 2004 -3.3 (1.607143) 100.0 % -3.30 [ -6.45, -0.15 ]
Subtotal (95% CI) 100.0 % -3.30 [ -6.45, -0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
4 Bronchiectasis
Chaudhuri 2004 -0.9 (1.836735) 100.0 % -0.90 [ -4.50, 2.70 ]
Subtotal (95% CI) 100.0 % -0.90 [ -4.50, 2.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
5 Idiopathic cough
Chaudhuri 2004 -1.4 (1.760204) 100.0 % -1.40 [ -4.85, 2.05 ]
Subtotal (95% CI) 100.0 % -1.40 [ -4.85, 2.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
6 All causes
Chaudhuri 2004 -2.1 (0.744898) 100.0 % -2.10 [ -3.56, -0.64 ]
Subtotal (95% CI) 100.0 % -2.10 [ -3.56, -0.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
Test for subgroup differences: Chi2 = 5.34, df = 5 (P = 0.38), I2 =6%
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Analysis 1.30. Comparison 1 ICS versus Placebo, Outcome 30 Change in exhaled CO [ppm].
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 30 Change in exhaled CO [ppm]
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 PNDS
Chaudhuri 2004 -0.1 (0.255102) 100.0 % -0.10 [ -0.60, 0.40 ]
Subtotal (95% CI) 100.0 % -0.10 [ -0.60, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
2 GORD
Chaudhuri 2004 -0.3 (0.357143) 100.0 % -0.30 [ -1.00, 0.40 ]
Subtotal (95% CI) 100.0 % -0.30 [ -1.00, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
3 CVA
Chaudhuri 2004 -0.3 (0.408163) 100.0 % -0.30 [ -1.10, 0.50 ]
Subtotal (95% CI) 100.0 % -0.30 [ -1.10, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
4 Bronchiectasis
Chaudhuri 2004 -0.7 (0.459184) 100.0 % -0.70 [ -1.60, 0.20 ]
Subtotal (95% CI) 100.0 % -0.70 [ -1.60, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
5 Idiopathic cough
Chaudhuri 2004 -0.1 (0.433673) 100.0 % -0.10 [ -0.95, 0.75 ]
Subtotal (95% CI) 100.0 % -0.10 [ -0.95, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
6 All causes
Chaudhuri 2004 -0.34 (0.163265) 100.0 % -0.34 [ -0.66, -0.02 ]
Subtotal (95% CI) 100.0 % -0.34 [ -0.66, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.037)
Test for subgroup differences: Chi2 = 1.64, df = 5 (P = 0.90), I2 =0.0%
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Analysis 1.31. Comparison 1 ICS versus Placebo, Outcome 31 Proportion with adverse effects.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 31 Proportion with adverse effects
Study or subgroup ICS Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pizzichini 1999 (1) 3/21 1/23 4.8 % 3.67 [ 0.35, 38.34 ]
Ponsioen 2005 10/65 9/68 43.6 % 1.19 [ 0.45, 3.15 ]
Ribeiro 2007 2/44 0/20 3.8 % 2.41 [ 0.11, 52.57 ]
Rytila¨ 2008 18/70 11/70 47.9 % 1.86 [ 0.80, 4.29 ]
Total (95% CI) 200 181 100.0 % 1.67 [ 0.92, 3.04 ]
Total events: 33 (ICS), 21 (Placebo)
Heterogeneity: Chi2 = 1.01, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
Test for subgroup differences: Not applicable
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Analysis 1.32. Comparison 1 ICS versus Placebo, Outcome 32 Proportion with specific adverse effects.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 32 Proportion with specific adverse effects
Study or subgroup ICS Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Hoarseness
Ponsioen 2005 (1) 9/65 10/68 0.93 [ 0.35, 2.47 ]
Ribeiro 2007 0/44 0/29 0.0 [ 0.0, 0.0 ]
2 Sore throat
Ponsioen 2005 0/65 1/68 0.34 [ 0.01, 8.59 ]
Ribeiro 2007 2/44 0/20 2.41 [ 0.11, 52.57 ]
3 Oral candidiasis
Ponsioen 2005 1/65 0/68 3.19 [ 0.13, 79.63 ]
Ribeiro 2007 0/44 0/29 0.0 [ 0.0, 0.0 ]
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Analysis 1.33. Comparison 1 ICS versus Placebo, Outcome 33 Proportion with severe adverse effects.
Review: Inhaled corticosteroids for subacute and chronic cough in adults
Comparison: 1 ICS versus Placebo
Outcome: 33 Proportion with severe adverse effects
Study or subgroup ICS Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ponsioen 2005 0/65 0/68 0.0 [ 0.0, 0.0 ]
Ribeiro 2007 0/44 0/29 0.0 [ 0.0, 0.0 ]
Rytila¨ 2008 (1) 5/70 6/70 0.82 [ 0.24, 2.82 ]
0.002 0.1 1 10 500
Favours ICS Favours Placebo
coughing, dyspnoea
(1) ICS group: dizziness, unspecified ear disorder, throat irritation, sinusitis, musculoskeletal pain; Placebo group: influenza-like symptoms, toothache, coughing, sinusitis,
aggravated
A P P E N D I C E S
Appendix 1. CAGR search strategy
((steroid* or corticosteroid* or glucocorticosteroid* or glucocorticoid* or corticoid*) AND (inhal*)) or beclomethasone or budesonide
or fluticasone or ciclesonide or mometasone or flunisolide or triamcinolone
[Limited to cough records]
Appendix 2. CENTRAL search strategy
#1 MeSH descriptor Cough explode all trees
#2 cough*
#3 (#1 OR #2)
#4 MeSH descriptor Adrenal Cortex Hormones explode all trees
#5 (steroid* or corticosteroid* or glucocorticosteroid* or glucocorticoid* or corticoid*) AND (inhal*)
#6 beclomethasone or budesonide or fluticasone or ciclesonide or mometasone or flunisolide or mometasone
#7 (#4 OR #5 OR #6)
#8 (#3 AND #7)
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Appendix 3. MEDLINE search strategy
1. ((steroid* or corticosteroid* or glucocorticosteroid* or glucocorticoid* or corticoid*) adj3 inhal*).tw.
2. (beclomethasone or budesonide or fluticasone or ciclesonide or mometasone or flunisolide or triamcinolone).tw.
3. exp Glucocorticoids/
4. 1 or 2 or 3
5. Cough/
6. (cough$ adj5 (chronic$ or sub-acute or subacute)).tw.
7. 5 or 6
8. 4 and 7
9. (clinical trial or controlled clinical trial or randomised controlled trial).pt.
10. (randomised or randomised).ab,ti.
11. placebo.ab,ti.
12. dt.fs.
13. randomly.ab,ti.
14. trial.ab,ti.
15. groups.ab,ti.
16. or/9-15
17. Animals/
18. Humans/
19. 17 not (17 and 18)
20. 16 not 19
21. 8 and 20
Appendix 4. EMBASE search strategy
1. ((steroid* or corticosteroid* or glucocorticosteroid* or glucocorticoid* or corticoid*) adj3 inhal*).tw.
2. (beclomethasone or budesonide or fluticasone or ciclesonide or mometasone or flunisolide or triamcinolone).tw.
3. exp coughing/
4. (cough$ adj5 (chronic$ or sub-acute or subacute)).tw.
5. 1 or 2
6. 3 or 4
7. 5 and 6
8. Randomized Controlled Trial/
9. randomisation/
10. Controlled Study/
11. Clinical Trial/
12. controlled clinical trial/
13. Double Blind Procedure/
14. Single Blind Procedure/
15. Crossover Procedure/
16. or/8-15
17. (clinica$ adj3 trial$).mp.
18. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (mask$ or blind$ or method$)).mp.
19. exp Placebo/
20. placebo$.mp.
21. random$.mp.
22. ((control$ or prospectiv$) adj3 (trial$ or method$ or stud$)).mp.
23. (crossover$ or cross-over$).mp.
24. or/17-23
25. 16 or 24
26. exp ANIMAL/
27. Nonhuman/
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28. Human/
29. 26 or 27
30. 29 not 28
31. 25 not 30
32. 7 and 31
Appendix 5. ClinicalTrials.gov search strategy
Study type: Interventional studies
Conditions: Chronic cough
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Criteria for considering studies for this review
Types of participants
• BHR was removed as an exclusion criterion for types of participants.
• We included one study where people as young as 15 (years) were eligible for inclusion (Evald 1989).
• We included one study of cough for at least two weeks (Ponsioen 2005). Unpublished data excluding people with acute cough
was used when available.
Types of outcome measures
The following additional secondary outcomes were recorded and analysed:
• Proportion of participants with a greater than 50% reduction in cough severity measure at follow up.
• Proportion of participants with clinical cure at follow up.
• Mean change in pulmonary function measures (spirometry, peak expiratory flow (PEF)).
• Biomarkers of inflammation - sputum biomarkers (total and differential cell counts, inflammatory mediators), exhaled gases.
Where a study reported two or more cough severity measures of equal ranking on the hierarchy of cough severity measures, the measure
most comparable to those used by other studies for the same outcome comparison was used in meta-analysis.
Search methods for identification of studies
With regard to contacting experts in the field, we contacted only the authors of identified trials, and we searched manufacturers’ online
clinical trial registries, rather than contact manufacturers directly.
Data collection and analysis
Cross-over trials were included in pooled data where first period data were available. Where these were not available, data were analysed
using the generic inverse variance method.
We explored publication bias using a funnel plot when meta-analysis with at least ten studies was possible.
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